Drugname	NCIDS:Phase:Status:Literature	Targets
thiotepa	NCT00002515:Phase 2:Completed:No publish	No
topotecan	NCT00002515:Phase 2:Completed:No publish	No
mesna	NCT00002854:Phase 1:Completed:No publish	No
ifosfamide	NCT00002854:Phase 1:Completed:No publish;;NCT00003597:Phase 1:Completed:Angiolillo AL, Davenport V, Bonilla MA, van de Ven C, Ayello J, Militano O, Miller LL, Krailo M, Reaman G, Cairo MS; Children's Oncology Group. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Clin Cancer Res. 2005 Apr 1;11(7):2644-50.	No
cisplatin-e	NCT00003044:Phase 2:Unknown status:No publish	No
pegylated	NCT00003296:Phase 2:Unknown status:No publish;;NCT00630084:Phase 4:Completed:No publish	No
tamoxifen	NCT00003424:Phase 3:Completed:No publish;;NCT00537771:Phase 4:Completed:No publish	Tamoxifen:ESR1#p.E380Q耐药性增加||ESR1#p.P535H耐药性增加
aminocamptothecin	NCT00003548:Phase 1:Completed:No publish	No
dolastatin	NCT00003557:Phase 2:Completed:No publish	No
carboplatin	NCT00003912:Phase 3:Completed:Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613.;;NCT00875615:Phase 2:Completed:No publish;;NCT00077389:Phase 2:Unknown status:No publish;;NCT00003994:Phase 3:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00486356:Phase 1:Completed:No publish;;NCT00021047:Phase 1|Phase 2:Completed:No publish;;NCT00007813:Phase 1:Unknown status:Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998 Nov;22(10):971-9.;;NCT00002515:Phase 2:Completed:No publish;;NCT00303940:Phase 1:Completed:Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E. Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst. 2010 Jun 16;102(12):909-12. doi: 10.1093/jnci/djq174. Epub 2010 May 11.;;NCT00002854:Phase 1:Completed:No publish;;NCT02755311:Phase 3:Unknown status:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT00003597:Phase 1:Completed:Angiolillo AL, Davenport V, Bonilla MA, van de Ven C, Ayello J, Militano O, Miller LL, Krailo M, Reaman G, Cairo MS; Children's Oncology Group. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Clin Cancer Res. 2005 Apr 1;11(7):2644-50.	No
cisplatin	NCT00003912:Phase 3:Completed:Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613.;;NCT00875615:Phase 2:Completed:No publish;;NCT00276705:Phase 2:Unknown status:No publish;;NCT00652132:Phase 3:Completed:No publish;;NCT00003907:Phase 2:Completed:No publish;;NCT00077389:Phase 2:Unknown status:No publish;;NCT01042041:Phase 1:Completed:No publish;;NCT00003994:Phase 3:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00304135:Phase 2|Phase 3:Completed:Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: F��d��ration Francophone de Canc��rologie Digestive 9902 phase II randomised study. Eur J Cancer. 2014 Nov;50(17):2975-82. doi: 10.1016/j.ejca.2014.08.013. Epub 2014 Sep 17.;;NCT01004978:Phase 3:Active, not recruiting:No publish;;NCT00980460:Phase 3:Active, not recruiting:No publish;;NCT00010023:Phase 1:Completed:Chen TT, Ryan T, Potmesil M, et al.: Cisplatin/capecitabine: tolerance and activity in patients with upper gastrointestinal cancers. [Abstract] American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium, 22-24 January 2004, San Francisco, CA. A-53, 2004.;;NCT00002854:Phase 1:Completed:No publish;;NCT00843934:Phase 2|Phase 3:Unknown status:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT03268499:Phase 2:Recruiting:No publish;;NCT02967887:Phase 2:Recruiting:No publish;;NCT00524498:Phase 2:Completed:No publish;;NCT00507962:Phase 1:Completed:No publish;;NCT00023868:Phase 3:Completed:No publish	No
doxorubicin	NCT00003912:Phase 3:Completed:Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. doi: 10.1056/NEJMoa0810613.;;NCT01011010:Phase 1:Completed:No publish;;NCT00004248:Phase 2:Completed:No publish;;NCT00012324:Phase 3:Completed:Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007 Jul 20;25(21):3069-75.;;NCT00471484:Phase 2:Unknown status:Ang MK, Poon D, Foo KF, Chung YF, Chow P, Wan WK, Thng CH, Ooi L. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematol Oncol Stem Cell Ther. 2008 Jul-Sep;1(3):159-65.;;NCT00079027:Phase 3:Unknown status:No publish;;NCT00276705:Phase 2:Unknown status:No publish;;NCT00047229:Phase 2:Completed:Knox JJ, Chen XE, Feld R, Nematollahi M, Cheiken R, Pond G, Zwiebel JA, Gill S, Moore M. A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798). Invest New Drugs. 2008 Apr;26(2):193-4. Epub 2007 Dec 4.;;NCT00006016:Phase 2:Completed:No publish;;NCT00003907:Phase 2:Completed:No publish;;NCT00077389:Phase 2:Unknown status:No publish;;NCT01042041:Phase 1:Completed:No publish;;NCT00083226:Phase 2:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00988195:Phase 1:Completed:No publish;;NCT01004978:Phase 3:Active, not recruiting:No publish;;NCT01015833:Phase 3:Active, not recruiting:No publish;;NCT00980460:Phase 3:Active, not recruiting:No publish;;NCT00019630:Phase 1:Completed:No publish;;NCT01858207:Phase 2:Unknown status:No publish;;NCT00720174:Phase 1:Completed:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT01272557:Phase 2:Unknown status:No publish;;NCT03145558:Phase 2:Recruiting:No publish;;NCT01840592:Phase 2:Active, not recruiting:No publish;;NCT01655693:Phase 3:Active, not recruiting:No publish;;NCT00990860:Phase 2:Unknown status:No publish;;NCT00471965:Phase 3:Completed:No publish;;NCT00023868:Phase 3:Completed:No publish	No
porfimer	NCT00003923:Phase 2:Completed:No publish	No
amifostine	NCT00003994:Phase 3:Completed:No publish	No
vincristine	NCT00003994:Phase 3:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00980460:Phase 3:Active, not recruiting:No publish;;NCT03017326:Phase 3:Recruiting:No publish	No
exatecan	NCT00004108:Phase 2:Completed:No publish;;NCT00005938:Phase 2:Completed:No publish	No
tipifarnib	NCT00005842:Phase 1:Completed:Schwartz G, Rowinsky EK, Rha SY, et al.: A phase I, pharmacokinetic, and biologic correlative study of R115777 and trastuzumab (herceptin) in patients with advanced cancer. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-322, 2001.	No
thalidomide	NCT00006006:Phase 2:Completed:Schwartz JD, Sung M, Schwartz M, Lehrer D, Mandeli J, Liebes L, Goldenberg A, Volm M. Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist. 2005 Oct;10(9):718-27.;;NCT00058487:Phase 2:Completed:Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005 Jun-Jul;10(6):392-8.;;NCT00276705:Phase 2:Unknown status:No publish;;NCT00006198:Phase 2:Unknown status:No publish;;NCT00006016:Phase 2:Completed:No publish;;NCT00728078:Phase 2|Phase 3:Unknown status:Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321-8.;;NCT00049296:Phase 1:Completed:Sanborn SL, Cooney MM, Dowlati A, Brell JM, Krishnamurthi S, Gibbons J, Bokar JA, Nock C, Ness A, Remick SC. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs. 2008 Aug;26(4):355-62. doi: 10.1007/s10637-008-9137-0. Epub 2008 May 10.;;NCT00155272:Phase 1|Phase 2:Unknown status:No publish;;NCT00921531:Phase 3:Unknown status:No publish;;NCT00519688:Phase 2:Completed:No publish	No
docetaxel	NCT00006010:Phase 2:Completed:Alberts SR, Reid JM, Morlan BW, Farr GH Jr, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol. 2012 Oct;35(5):418-23.;;NCT00049296:Phase 1:Completed:Sanborn SL, Cooney MM, Dowlati A, Brell JM, Krishnamurthi S, Gibbons J, Bokar JA, Nock C, Ness A, Remick SC. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs. 2008 Aug;26(4):355-62. doi: 10.1007/s10637-008-9137-0. Epub 2008 May 10.;;NCT00002901:Phase 1:Completed:No publish	No
tetrathiomolybdate	NCT00006332:Phase 2:Completed:No publish	No
nolatrexed	NCT00012324:Phase 3:Completed:Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol. 2007 Jul 20;25(21):3069-75.	No
ondansetron	NCT00016380:Phase 3:Completed:National Cancer Institute of Canada Clinical Trials Group (SC19), Wong RK, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Ackerman I, Souhami L, Chabot P, Pater J. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol. 2006 Jul 20;24(21):3458-64.	No
detoxpc	NCT00019331:Phase 2:Completed:No publish	No
hydroxyurea	NCT00019474:Phase 2:Unknown status:No publish	No
o6-benzylguanine	NCT00020150:Phase 1:Completed:Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol. 2009 Dec;65(1):137-42. doi: 10.1007/s00280-009-1015-8. Epub 2009 May 9.	No
folfiri	NCT00020501:Phase 3:Completed:No publish;;NCT00208260:Phase 2|Phase 3:Completed:No publish;;NCT00023868:Phase 3:Completed:No publish	No
entinostat	NCT00020579:Phase 1:Completed:Ryan QC, Headlee D, Sparreboom A, et al.: A phase I trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-802, 2003.	No
melphalan	NCT00030082:Phase 1:Completed:No publish;;NCT00001587:Phase 1:Completed:No publish;;NCT00019786:Phase 2:Completed:Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003 Dec 15;21(24):4560-7.;;NCT00001576:Phase 1:Completed:No publish;;NCT00096083:Phase 2:Completed:No publish;;NCT00103298:Phase 2:Completed:No publish;;NCT00089401:Phase 2:Completed:No publish;;NCT00020501:Phase 3:Completed:No publish;;NCT00019760:Phase 2:Completed:No publish	No
isolated	NCT00030082:Phase 1:Completed:No publish;;NCT00019786:Phase 2:Completed:Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003 Dec 15;21(24):4560-7.;;NCT00096083:Phase 2:Completed:No publish;;NCT00103298:Phase 2:Completed:No publish;;NCT00089401:Phase 2:Completed:No publish;;NCT00002692:Phase 3:Unknown status:Current version of study NCT00002692 on ClinicalTrials.gov;;NCT00006050:Phase 2:Unknown status:Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.	No
ixabepilone	NCT00030108:Phase 1:Completed:Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E. Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. J Clin Oncol. 2009 Feb 1;27(4):550-6. doi: 10.1200/JCO.2008.17.6644. Epub 2008 Dec 15.	No
7-hydroxystaurosporine	NCT00031681:Phase 1:Completed:No publish	No
abt-751	NCT00036959:Phase 1:Completed:Fox E, Maris JM, Cohn SL, Goodspeed W, Goodwin A, Kromplewski M, Medina D, Xiong H, Krivoshik A, Widemann B, Adamson PC, Balis FM. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol. 2010 Sep;66(4):737-43. doi: 10.1007/s00280-009-1218-z. Epub 2010 Jan 1.	No
megestrol	NCT00041275:Phase 3:Completed:Chow PK, Machin D, Chen Y, Zhang X, Win KM, Hoang HH, Nguyen BD, Jin MY, Lobo R, Findlay M, Lim CH, Tan SB, Gandhi M, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group. Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. Br J Cancer. 2011 Sep 27;105(7):945-52. doi: 10.1038/bjc.2011.333. Epub 2011 Aug 23.	No
intravenous	NCT00043433:Phase 2:Unknown status:No publish	No
bms-247550	NCT00049400:Phase 1:Completed:Current version of study NCT00049400 on ClinicalTrials.gov	No
t900607	NCT00054262:Phase 2:Completed:No publish	No
mtc-dox	NCT00054951:Phase 1|Phase 2:Unknown status:No publish;;NCT00041808:Phase 1|Phase 2:Completed:No publish	No
aroplatin	NCT00057395:Phase 1|Phase 2:Unknown status:No publish	No
celecoxib	NCT00057980:Phase 1|Phase 2:Completed:No publish;;NCT03059238:Phase 3:Recruiting:Lv N, Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol. 2016 Oct;26(10):3492-9. doi: 10.1007/s00330-016-4207-8. Epub 2016 Jan 22.;;NCT00081848:Phase 1:Completed:No publish;;NCT02961998:Phase 4:Completed:No publish;;NCT03403634:Early Phase 1:Recruiting:No publish	No
epirubicin	NCT00058487:Phase 2:Completed:Zhu AX, Fuchs CS, Clark JW, Muzikansky A, Taylor K, Sheehan S, Tam K, Yung E, Kulke MH, Ryan DP. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. Oncologist. 2005 Jun-Jul;10(6):392-8.;;NCT00057980:Phase 1|Phase 2:Completed:No publish;;NCT00486356:Phase 1:Completed:No publish;;NCT00021047:Phase 1|Phase 2:Completed:No publish;;NCT00843934:Phase 2|Phase 3:Unknown status:No publish;;NCT00820053:Phase 2:Completed:No publish;;NCT02755311:Phase 3:Unknown status:No publish;;NCT02631499:Phase 4:Not yet recruiting:No publish	No
boronophenylalanine-fructose	NCT00062348:Phase 1:Completed:Wittig A, Sheu-Grabellus SY, Collette L, Moss R, Brualla L, Sauerwein W. BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001). Appl Radiat Isot. 2011 Dec;69(12):1807-12. doi: 10.1016/j.apradiso.2011.02.018. Epub 2011 Feb 16.	No
gefitinib	NCT00071994:Phase 2:Completed:No publish	Gefitinib (吉非替尼):EGFR#p.G719A敏感性增加||EGFR#p.G719C敏感性增加||EGFR#p.G719D敏感性增加||EGFR#p.G719S敏感性增加||EGFR#p.L747S敏感性增加||EGFR#p.L858R敏感性增加||EGFR#p.L861P敏感性增加||EGFR#p.L861Q敏感性增加||EGFR#p.L861R敏感性增加||EGFR#p.S768I敏感性增加||EGFR#p.T790M耐药性增加||EGFR#p.V843I敏感性降低
mb07133	NCT00073736:Phase 1|Phase 2:Completed:No publish;;NCT00073736:Phase 1|Phase 2:Completed:No publish;;NCT00073736:Phase 1|Phase 2:Completed:No publish;;NCT00073736:Phase 1|Phase 2:Completed:No publish;;NCT00073736:Phase 1|Phase 2:Completed:No publish	No
forodesine	NCT00073944:Phase 1:Completed:No publish	No
phy906	NCT00076609:Phase 1|Phase 2:Completed:No publish	No
tac-101	NCT00077142:Phase 1|Phase 2:Completed:Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008 Dec;134(12):1325-35. doi: 10.1007/s00432-008-0406-2. Epub 2008 May 27.	No
idn-6556	NCT00080236:Phase 2:Completed:No publish	No
rv-cea(6d)/tricom-rf-cea(6d)/tricom	NCT00081848:Phase 1:Completed:No publish	No
rf-cea(6d)/tricom	NCT00081848:Phase 1:Completed:No publish	No
recombinant	NCT00081848:Phase 1:Completed:No publish;;NCT00187109:Phase 1|Phase 2:Completed:No publish;;NCT02662348:Phase 1:Unknown status:No publish;;NCT01869088:Phase 3:Active, not recruiting:Vogl TJ, Trapp M, Schroeder H, Mack M, Schuster A, Schmitt J, Neuhaus P, Felix R. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology. 2000 Feb;214(2):349-57.;;NCT03208335:Phase 2:Recruiting:No publish	No
bortezomib	NCT00083226:Phase 2:Completed:No publish;;NCT00077441:Phase 2:Completed:No publish;;NCT00091117:Phase 1:Completed:No publish	Bortezomib (硼替佐米):PSMB5#p.A49T耐药性增加||PSMB5#p.A49V耐药性增加||PSMB5#p.A50V耐药性增加||FGFR3#p.Y373C耐药性增加
alvocidib	NCT00087282:Phase 2:Completed:No publish;;NCT00012181:Phase 1:Completed:No publish	No
irinotecan	NCT00087282:Phase 2:Completed:No publish;;NCT00287976:Phase 2:Unknown status:No publish;;NCT00861783:Phase 1:Completed:Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.;;NCT00980239:Phase 1:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00143403:Phase 3:Completed:No publish;;NCT00537121:Phase 1:Completed:No publish;;NCT00980460:Phase 3:Active, not recruiting:No publish;;NCT00020501:Phase 3:Completed:No publish;;NCT00654160:Phase 1:Completed:No publish;;NCT00003427:Phase 1:Completed:Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002 Sep;13(9):1490-6.;;NCT00031681:Phase 1:Completed:No publish;;NCT01643499:Phase 1:Active, not recruiting:No publish;;NCT03493048:Phase 2:Recruiting:No publish;;NCT03493061:Phase 2:Recruiting:No publish;;NCT00101270:Phase 1:Completed:No publish;;NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT00003867:Phase 1:Unknown status:Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34.;;NCT03017326:Phase 3:Recruiting:No publish;;NCT00635323:Phase 2:Completed:No publish;;NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.;;NCT00408551:Phase 2:Unknown status:No publish;;NCT01226719:Phase 2:Completed:No publish;;NCT00513266:Phase 2:Unknown status:No publish;;NCT00023868:Phase 3:Completed:No publish;;NCT03069950:Phase 2:Recruiting:No publish;;NCT01802645:Phase 2:Recruiting:No publish;;NCT00063960:Phase 2:Completed:No publish;;NCT00557102:Phase 2:Completed:No publish;;NCT00003368:Phase 1:Completed:Venook AP, Enders Klein C, Fleming G, Hollis D, Leichman CG, Hohl R, Byrd J, Budman D, Villalona M, Marshall J, Rosner GL, Ramirez J, Kastrissios H, Ratain MJ. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol. 2003 Dec;14(12):1783-90.;;NCT00003753:Phase 2:Completed:No publish;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00037804:Phase 1:Completed:No publish;;NCT00030563:Phase 2:Completed:No publish	No
ns-9	NCT00094003:Phase 1:Completed:No publish	No
ispinesib	NCT00095992:Phase 2:Completed:Knox JJ, Gill S, Synold TW, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L. A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Invest New Drugs. 2008 Jun;26(3):265-72. doi: 10.1007/s10637-007-9103-2. Epub 2008 Jan 15.	No
lapatinib	NCT00101036:Phase 2:Completed:No publish;;NCT00107536:Phase 2:Completed:Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009 Sep 15;15(18):5895-901. doi: 10.1158/1078-0432.CCR-09-0465. Epub 2009 Sep 8.;;NCT02015169:Phase 2:Completed:No publish	Lapatinib (拉帕替尼):ERBB2#p.D769H敏感性增加||ERBB2#p.D769Y敏感性增加||ERBB4#p.E317K敏感性增加||ERBB4#p.E452K敏感性增加||EGFR#p.E690K敏感性增加||ERBB4#p.E872K敏感性增加||ERBB3#p.G284R敏感性增加||ERBB2#p.G309A敏感性增加||ERBB4#p.H809G耐药性增加||ERBB2#p.K753E耐药性增加||ERBB3#p.P262H敏感性增加||ERBB3#p.Q809R敏感性增加||ERBB4#p.R393W敏感性增加||ERBB4#p.R544W敏感性增加||ERBB2#p.R896C敏感性增加||ERBB2#p.V659E敏感性增加||ERBB2#p.V777L敏感性增加||ERBB2#p.V842I敏感性增加
doxorubicin/placebo	NCT00108953:Phase 2:Completed:Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.	No
131	NCT00116454:Phase 3:Completed:No publish	No
talaporfin	NCT00122876:Phase 1|Phase 2:Completed:No publish	No
arsenic	NCT00128596:Phase 2:Completed:No publish;;NCT00024258:Phase 2:Completed:No publish;;NCT02956772:Phase 2:Not yet recruiting:No publish	No
folinic	NCT00143403:Phase 3:Completed:No publish;;NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT02885753:Phase 3:Recruiting:No publish;;NCT01802645:Phase 2:Recruiting:No publish	No
nv1020	NCT00149396:Phase 1|Phase 2:Completed:No publish	No
ifn-α2b	NCT00149565:Phase 3:Completed:No publish	No
perioperative	NCT00168155:Phase 2:Completed:No publish	No
mitomycin-c,	NCT00183885:Phase 2:Active, not recruiting:No publish	No
pemetrexed	NCT00191412:Phase 2:Completed:No publish;;NCT00059865:Phase 1|Phase 2:Completed:Alberts SR, Sande JR, Foster NR, Quevedo FJ, McWilliams RR, Kugler JW, Fitch TR, Jaslowski AJ. Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. J Gastrointest Cancer. 2007;38(2-4):87-94. doi: 10.1007/s12029-008-9037-8. Epub 2008 Nov 21.	No
folfox-4	NCT00208260:Phase 2|Phase 3:Completed:No publish	No
folfiri-hd	NCT00208260:Phase 2|Phase 3:Completed:No publish	No
folfox-7	NCT00208260:Phase 2|Phase 3:Completed:No publish	No
folfirinox	NCT00208260:Phase 2|Phase 3:Completed:No publish	No
interferon	NCT00234182:Phase 1|Phase 2:Completed:No publish;;NCT00273247:Phase 3:Completed:No publish;;NCT01834963:Phase 2:Recruiting:No publish	No
cediranib	NCT00238394:Phase 2:Completed:No publish	No
pi-88	NCT00247728:Phase 2:Completed:No publish	No
thalidomide,	NCT00250796:Phase 2:Completed:No publish;;NCT00250796:Phase 2:Completed:No publish	No
octreotide	NCT00257426:Phase 2:Completed:No publish;;NCT00241020:Phase 3:Completed:No publish	No
adh300004	NCT00264446:Phase 1:Completed:No publish	No
patupilone	NCT00273312:Phase 2:Completed:Zhou Q, Wong CH, Lau CP, Hui CW, Lui VW, Chan SL, Yeo W. Enhanced Antitumor Activity with Combining Effect of mTOR Inhibition and Microtubule Stabilization in Hepatocellular Carcinoma. Int J Hepatol. 2013;2013:103830. doi: 10.1155/2013/103830. Epub 2013 Feb 20.	No
cyclophosphamide	NCT00276705:Phase 2:Unknown status:No publish;;NCT03159585:Phase 1:Recruiting:No publish;;NCT02869217:Phase 1:Recruiting:No publish;;NCT01967823:Phase 2:Recruiting:No publish;;NCT00007813:Phase 1:Unknown status:Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998 Nov;22(10):971-9.;;NCT00002854:Phase 1:Completed:No publish;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT03084380:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT01174121:Phase 2:Recruiting:No publish;;NCT00656123:Phase 1:Unknown status:No publish	No
e7337	NCT00280410:Phase 2|Phase 3:Completed:No publish	No
iressa	NCT00282100:Phase 2:Unknown status:No publish	No
talabostat	NCT00303940:Phase 1:Completed:Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E. Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst. 2010 Jun 16;102(12):909-12. doi: 10.1093/jnci/djq174. Epub 2010 May 11.	No
temozolomide	NCT00303940:Phase 1:Completed:Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E. Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst. 2010 Jun 16;102(12):909-12. doi: 10.1093/jnci/djq174. Epub 2010 May 11.;;NCT00020150:Phase 1:Completed:Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol. 2009 Dec;65(1):137-42. doi: 10.1007/s00280-009-1015-8. Epub 2009 May 9.;;NCT00526617:Phase 1:Completed:Nuthalapati S, Munasinghe W, Giranda V, Xiong H. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. Clin Pharmacokinet. 2018 Jan;57(1):51-58. doi: 10.1007/s40262-017-0547-z.	No
belinostat	NCT00321594:Phase 1|Phase 2:Completed:No publish	No
crs-100	NCT00327652:Phase 1:Completed:No publish	No
embolization	NCT00335829:Phase 2:Completed:No publish;;NCT00028626:Phase 2:Completed:No publish	No
chemotherapy	NCT00335829:Phase 2:Completed:No publish;;NCT02862587:Phase 1|Phase 2:Recruiting:No publish;;NCT01564810:Phase 4:Unknown status:No publish;;NCT01307878:Phase 4:Unknown status:No publish;;NCT02363049:Phase 3:Recruiting:No publish;;NCT00849264:Phase 2:Completed:No publish;;NCT03511703:Phase 2:Not yet recruiting:No publish;;NCT02738606:Phase 2:Recruiting:No publish	No
cni,	NCT00355862:Phase 3:Completed:No publish	No
su011248	NCT00361309:Phase 2:Completed:No publish	No
nicotine	NCT00365508:Phase 4:Completed:No publish;;NCT00365508:Phase 4:Completed:No publish	No
pazopanib	NCT00370513:Phase 1:Completed:No publish;;NCT00674024:Phase 1:Completed:No publish;;NCT00674024:Phase 1:Completed:No publish	No
irofulven	NCT00374660:Phase 1|Phase 2:Unknown status:No publish	No
interferon-alfa-2b	NCT00375661:Phase 4:Completed:No publish	No
thalidomide(thado),	NCT00384800:Phase 2:Unknown status:No publish	No
perifosine	NCT00398814:Phase 1:Completed:Preliminary results / Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 16024	No
floxuridine	NCT00410956:Phase 2:Active, not recruiting:Kemeny NE, Schwartz L, G nen M, Yopp A, Gultekin D, D'Angelica MI, Fong Y, Haviland D, Gewirtz AN, Allen P, Jarnagin WR. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology. 2011;80(3-4):153-9. doi: 10.1159/000324704. Epub 2011 Jun 14.;;NCT00001576:Phase 1:Completed:No publish;;NCT00587067:Phase 2:Completed:No publish;;NCT01525069:Phase 1:Recruiting:No publish;;NCT00020501:Phase 3:Completed:No publish;;NCT02529774:Phase 2|Phase 3:Not yet recruiting:No publish;;NCT03493061:Phase 2:Recruiting:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT00019760:Phase 2:Completed:No publish;;NCT00005860:Phase 1:Completed:No publish;;NCT00408551:Phase 2:Unknown status:No publish;;NCT00004142:Phase 2:Completed:No publish;;NCT03069950:Phase 2:Recruiting:No publish;;NCT00063960:Phase 2:Completed:No publish;;NCT00002716:Phase 3:Completed:Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403. Epub 2006 Feb 27.;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.;;NCT00003753:Phase 2:Completed:No publish;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00002842:Phase 2:Completed:No publish;;NCT00026234:Phase 2:Completed:No publish	No
dexamethasone	NCT00410956:Phase 2:Active, not recruiting:Kemeny NE, Schwartz L, G nen M, Yopp A, Gultekin D, D'Angelica MI, Fong Y, Haviland D, Gewirtz AN, Allen P, Jarnagin WR. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology. 2011;80(3-4):153-9. doi: 10.1159/000324704. Epub 2011 Jun 14.;;NCT01525069:Phase 1:Recruiting:No publish;;NCT00016380:Phase 3:Completed:National Cancer Institute of Canada Clinical Trials Group (SC19), Wong RK, Paul N, Ding K, Whitehead M, Brundage M, Fyles A, Wilke D, Nabid A, Fortin A, Wilson D, McKenzie M, Ackerman I, Souhami L, Chabot P, Pater J. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol. 2006 Jul 20;24(21):3458-64.;;NCT02987907:Phase 3:Recruiting:No publish;;NCT03069950:Phase 2:Recruiting:No publish;;NCT00002716:Phase 3:Completed:Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403. Epub 2006 Feb 27.;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.;;NCT00003753:Phase 2:Completed:No publish;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00026234:Phase 2:Completed:No publish	No
darinaparsin	NCT00423306:Phase 2:Unknown status:No publish	No
thermodox	NCT00441376:Phase 1:Completed:No publish;;NCT00617981:Phase 3:Completed:No publish;;NCT02112656:Phase 3:Recruiting:No publish	No
thymopentin	NCT00460681:Phase 3:Unknown status:No publish	No
rapamycin	NCT00467194:Phase 1:Completed:No publish;;NCT00375245:Phase 1:Completed:No publish;;NCT02724332:Phase 1:Completed:No publish	No
fluorouracil	NCT00471484:Phase 2:Unknown status:Ang MK, Poon D, Foo KF, Chung YF, Chow P, Wan WK, Thng CH, Ooi L. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematol Oncol Stem Cell Ther. 2008 Jul-Sep;1(3):159-65.;;NCT00003994:Phase 3:Completed:No publish;;NCT00507585:Phase 1:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT01775501:Phase 2:Active, not recruiting:No publish;;NCT00537121:Phase 1:Completed:No publish;;NCT00009893:Phase 2:Completed:Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 2005 Jan 1;103(1):111-8.;;NCT00980460:Phase 3:Active, not recruiting:No publish;;NCT00103298:Phase 2:Completed:No publish;;NCT00020501:Phase 3:Completed:No publish;;NCT00019474:Phase 2:Unknown status:No publish;;NCT00654160:Phase 1:Completed:No publish;;NCT00019513:Phase 1:Completed:No publish;;NCT02042443:Phase 2:Completed:No publish;;NCT01643499:Phase 1:Active, not recruiting:No publish;;NCT01055743:Phase 2:Unknown status:No publish;;NCT00559455:Phase 2:Completed:No publish;;NCT00408551:Phase 2:Unknown status:No publish;;NCT00004142:Phase 2:Completed:No publish;;NCT00438737:Phase 2:Unknown status:No publish;;NCT00002793:Phase 3:Unknown status:No publish;;NCT00006479:Phase 3:Unknown status:Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009 Sep;16(9):2385-90. doi: 10.1245/s10434-009-0492-7. Epub 2009 Jun 25. Review.;;NCT00002692:Phase 3:Unknown status:Current version of study NCT00002692 on ClinicalTrials.gov;;NCT00482222:Phase 3:Unknown status:No publish;;NCT00513266:Phase 2:Unknown status:No publish;;NCT00003834:Phase 2:Completed:Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20;23(36):9243-9. Epub 2005 Oct 17.;;NCT00023868:Phase 3:Completed:No publish;;NCT03069950:Phase 2:Recruiting:No publish;;NCT00006050:Phase 2:Unknown status:Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.;;NCT00544349:Phase 2:Completed:No publish;;NCT00002716:Phase 3:Completed:Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403. Epub 2006 Feb 27.;;NCT00557102:Phase 2:Completed:No publish;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00002842:Phase 2:Completed:No publish;;NCT00056030:Phase 2:Completed:No publish;;NCT00427310:Phase 3:Completed:O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010 Sep 1;28(25):3937-44. doi: 10.1200/JCO.2010.28.9538. Epub 2010 Aug 2.	No
azd0530	NCT00475956:Phase 1:Completed:No publish	No
ngr-htnf	NCT00484211:Phase 2:Completed:Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. Br J Cancer. 2010 Sep 7;103(6):837-44. doi: 10.1038/sj.bjc.6605858. Epub 2010 Aug 17.	No
octreotide-lar,	NCT00495846:Phase 2|Phase 3:Completed:Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, Roberts S, Poon A, Scott AM, Kalff V, Garas G, Dowling A, Crawford D, Ring J, Basser R, Strickland A, Macdonald G, Green M, Nowak A, Dickman B, Dhillon H, Gebski V; Australasian Gastro-Intestinal Trials Group (AGITG) Ag0001H Investigators. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer. 2006 Oct 9;95(7):853-61. Epub 2006 Sep 5. Erratum in: Br J Cancer. 2007 Apr 10;96(7):1154. Findlay, M [added]; Hargreaves, C [added]; Stockler, M [added]; Thompson, P [added]; Boyer, M [added]; Roberts, S [added]; Poon, A [added]; Scott, A M [added]; Kalff, V [added]; Garas, G [added]; Dowling, A [added]; Crawford, D [added]; Ring, J [added]; Ba.	No
zd6474	NCT00496509:Phase 1:Completed:No publish;;NCT00496509:Phase 1:Completed:No publish	No
azd2171	NCT00501605:Phase 1:Completed:No publish;;NCT00475956:Phase 1:Completed:No publish	No
avastin	NCT00507585:Phase 1:Completed:No publish	No
leucovorin	NCT00507585:Phase 1:Completed:No publish;;NCT00001576:Phase 1:Completed:No publish;;NCT01775501:Phase 2:Active, not recruiting:No publish;;NCT00537121:Phase 1:Completed:No publish;;NCT00009893:Phase 2:Completed:Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 2005 Jan 1;103(1):111-8.;;NCT00103298:Phase 2:Completed:No publish;;NCT00020501:Phase 3:Completed:No publish;;NCT00654160:Phase 1:Completed:No publish;;NCT00019513:Phase 1:Completed:No publish;;NCT02042443:Phase 2:Completed:No publish;;NCT01643499:Phase 1:Active, not recruiting:No publish;;NCT03493048:Phase 2:Recruiting:No publish;;NCT03500874:Phase 3:Recruiting:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT00019760:Phase 2:Completed:No publish;;NCT00005860:Phase 1:Completed:No publish;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT00559455:Phase 2:Completed:No publish;;NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.;;NCT00408551:Phase 2:Unknown status:No publish;;NCT00438737:Phase 2:Unknown status:No publish;;NCT01226719:Phase 2:Completed:No publish;;NCT00803647:Phase 2:Completed:No publish;;NCT00002793:Phase 3:Unknown status:No publish;;NCT00006479:Phase 3:Unknown status:Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009 Sep;16(9):2385-90. doi: 10.1245/s10434-009-0492-7. Epub 2009 Jun 25. Review.;;NCT00002692:Phase 3:Unknown status:Current version of study NCT00002692 on ClinicalTrials.gov;;NCT00482222:Phase 3:Unknown status:No publish;;NCT00513266:Phase 2:Unknown status:No publish;;NCT00003834:Phase 2:Completed:Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20;23(36):9243-9. Epub 2005 Oct 17.;;NCT00023868:Phase 3:Completed:No publish;;NCT03069950:Phase 2:Recruiting:No publish;;NCT00006050:Phase 2:Unknown status:Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.;;NCT00544349:Phase 2:Completed:No publish;;NCT00002716:Phase 3:Completed:Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE 2nd, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395-403. Epub 2006 Feb 27.;;NCT00557102:Phase 2:Completed:No publish;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00002842:Phase 2:Completed:No publish;;NCT00056030:Phase 2:Completed:No publish	No
vandetanib	NCT00508001:Phase 2:Completed:No publish	Vandetanib (凡德他尼):RET#p.C634W敏感性增加||RET#p.M918T敏感性增加||RET#p.M918T敏感性增加||ABL1#p.V299L敏感性增加||BRAF#p.V600E敏感性增加||RET#p.V804M耐药性增加
s-adenosyl-l-methionine	NCT00513461:Phase 2:Unknown status:No publish	No
rad001	NCT00516165:Phase 1|Phase 2:Completed:No publish;;NCT00390195:Phase 1|Phase 2:Unknown status:Shiah HS, Chen CY, Dai CY, Hsiao CF, Lin YJ, Su WC, Chang JY, Whang-Peng J, Lin PW, Huang JD, Chen LT. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2013 Jan;37(1):62-73. doi: 10.1111/apt.12132. Epub 2012 Nov 8.|Treiber G. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther. 2009 Feb;9(2):247-61. doi: 10.1586/14737140.9.2.247. Review.	No
abt-869	NCT00517920:Phase 2:Completed:No publish	No
tegafur/uracil	NCT00519688:Phase 2:Completed:No publish;;NCT00464919:Phase 2:Completed:No publish	No
opc-18	NCT00524498:Phase 2:Completed:No publish	No
abt-888	NCT00526617:Phase 1:Completed:Nuthalapati S, Munasinghe W, Giranda V, Xiong H. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies. Clin Pharmacokinet. 2018 Jan;57(1):51-58. doi: 10.1007/s40262-017-0547-z.	No
anastrozole	NCT00537771:Phase 4:Completed:No publish	No
fentanyl	NCT00538850:Phase 3:Completed:Rauck R, Reynolds L, Geach J, Bull J, Stearns L, Scherlis M, Parikh N, Dillaha L. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012 May;28(5):859-70. doi: 10.1185/03007995.2012.683111. Epub 2012 May 2.	No
indocyanine	NCT00540982:Phase 1|Phase 2:Completed:No publish	No
lidocaine	NCT00540982:Phase 1|Phase 2:Completed:No publish	No
vinorelbine	NCT00540982:Phase 1|Phase 2:Completed:No publish	No
endotag®-1	NCT00542048:Phase 2:Completed:No publish	No
lamivudine	NCT00555334:Phase 4:Unknown status:No publish;;NCT01936233:Phase 3:Unknown status:No publish;;NCT02650271:Phase 2|Phase 3:Recruiting:Ke Y, Ma L, You XM, Huang SX, Liang YR, Xiang BD, Li LQ, Zhong JH. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med. 2013 Sep;10(3):158-64. doi: 10.7497/j.issn.2095-3941.2013.03.006.;;NCT01894269:Phase 4:Unknown status:No publish	No
nadolol	NCT00567216:Phase 4:Unknown status:No publish	No
atropine	NCT00575523:Phase 4:Completed:No publish	No
selumetinib	NCT00604721:Phase 2:Completed:No publish;;NCT00553332:Phase 2:Completed:Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.	Selumetinib:HRAS#p.G12R敏感性增加||HRAS#p.G12V敏感性增加||HRAS#p.G13C敏感性增加||HRAS#p.G13R敏感性增加||GNA11#p.Q209L敏感性增加||GNAQ#p.Q209L敏感性增加||GNA11#p.Q209P敏感性增加||NRAS#p.Q61K敏感性增加||HRAS#p.Q61R敏感性增加||BRAF#p.V600E敏感性增加
erlotinib	NCT00605722:Phase 2:Completed:No publish;;NCT00881751:Phase 2:Completed:No publish;;NCT00365391:Phase 2:Completed:No publish;;NCT00242502:Phase 2:Completed:No publish;;NCT01180959:Phase 2:Active, not recruiting:No publish;;NCT00047346:Phase 1:Completed:No publish;;NCT02273362:Phase 1|Phase 2:Recruiting:No publish;;NCT00987766:Phase 1:Completed:No publish;;NCT00033462:Phase 2:Completed:No publish;;NCT00397384:Phase 1:Completed:No publish;;NCT00030498:Phase 1:Completed:No publish;;NCT00901901:Phase 3:Completed:No publish;;NCT00287222:Phase 2:Completed:No publish	Erlotinib (厄洛替尼):EGFR#p.A289V敏感性增加||EGFR#p.D761Y耐药性增加||EGFR#p.E746G敏感性增加||EGFR#p.G598V敏感性增加||EGFR#p.K757R敏感性增加||EGFR#p.L858R敏感性增加||EGFR#p.L858R敏感性增加||EGFR#p.R108K敏感性增加||EGFR#p.S768I敏感性增加||DDR2#p.S768R敏感性增加||EGFR#p.T263P敏感性增加||EGFR#p.T790M耐药性增加
dasatinib	NCT00608361:Phase 1:Completed:No publish;;NCT02465060:Phase 2:Recruiting:No publish	Dasatinib (达沙替尼):CBL#p.C384R敏感性增加||ABL1#p.D444Y耐药性增加||KIT#p.D816F敏感性增加||KIT#p.D816V敏感性增加||KIT#p.D816V敏感性增加||KIT#p.D816V敏感性增加||KIT#p.D816Y敏感性增加||PDGFRA#p.D842V敏感性增加||ABL1#p.E255K敏感性增加||ABL1#p.E255V敏感性增加||ABL1#p.E355G耐药性增加||ABL1#p.F317C耐药性增加||ABL1#p.F317I耐药性增加||ABL1#p.F317L耐药性增加||ABL1#p.F317R.||ABL1#p.F317V耐药性增加||ABL1#p.F359C敏感性增加||ABL1#p.F359I敏感性增加||ABL1#p.F359V敏感性增加||ABL1#p.G250E.||DDR2#p.G253C敏感性增加||EPHA2#p.G391R敏感性增加||BRAF#p.G466V敏感性增加||DDR2#p.G505S敏感性增加||DDR2#p.G774V敏感性增加||DDR2#p.I638F敏感性增加||DDR2#p.L239R敏感性增加||ABL1#p.L273M耐药性增加||KIT#p.L576P敏感性增加||DDR2#p.L63V敏感性增加||KIT#p.N822K敏感性增加||DDR2#p.S768R敏感性增加||ABL1#p.T315A耐药性增加||ABL1#p.T315I耐药性增加||ABL1#p.T495R耐药性增加||CSF3R#p.T615A敏感性增加||CSF3R#p.T618I敏感性增加||SRC#p.V140M||ABL1#p.V299L耐药性增加||ABL1#p.V379I耐药性增加||ABL1#p.Y253F耐药性增加||ABL1#p.Y253H敏感性增加||ABL1#p.Y353H耐药性增加||CBL#p.Y371H敏感性增加||BRAF#p.Y472C敏感性增加
5%	NCT00617981:Phase 3:Completed:No publish	No
infusional	NCT00619541:Phase 2:Completed:No publish	No
sodium	NCT00652132:Phase 3:Completed:No publish;;NCT00716976:Phase 3:Completed:No publish;;NCT00062348:Phase 1:Completed:Wittig A, Sheu-Grabellus SY, Collette L, Moss R, Brualla L, Sauerwein W. BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001). Appl Radiat Isot. 2011 Dec;69(12):1807-12. doi: 10.1016/j.apradiso.2011.02.018. Epub 2011 Feb 16.;;NCT00427310:Phase 3:Completed:O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol. 2010 Sep 1;28(25):3937-44. doi: 10.1200/JCO.2010.28.9538. Epub 2010 Aug 2.	No
neoadjuvant	NCT00659022:Phase 2:Unknown status:No publish;;NCT00630045:Phase 3:Unknown status:No publish	No
neo-adjuvant	NCT00659022:Phase 2:Unknown status:No publish;;NCT00659022:Phase 2:Unknown status:No publish	No
gm-csf	NCT00661622:Phase 2:Completed:No publish	No
bupropion	NCT00666978:Phase 4:Completed:No publish;;NCT00534001:Phase 2:Completed:No publish	No
nexavar	NCT00692770:Phase 3:Completed:Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.	No
infusion	NCT00706576:Phase 1:Completed:No publish	No
ms-20	NCT00707681:Phase 2:Unknown status:No publish	No
lenalidomide	NCT00717756:Phase 2:Completed:Safran H, Charpentier KP, Kaubisch A, Mantripragada K, Dubel G, Perez K, Faricy-Anderson K, Miner T, Eng Y, Victor J, Plette A, Espat J, Bakalarski P, Wingate P, Berz D, Luppe D, Martel D, Rosati K, Aparo S. Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study. Am J Clin Oncol. 2015 Feb;38(1):1-4. doi: 10.1097/COC.0b013e3182868c66.;;NCT01545804:Phase 2:Completed:No publish	No
z-208	NCT00731445:Phase 1|Phase 2:Completed:No publish	No
hai	NCT00732836:Phase 1:Completed:No publish;;NCT00200200:Phase 2:Active, not recruiting:No publish;;NCT00852228:Phase 2:Unknown status:No publish;;NCT00852228:Phase 2:Unknown status:No publish;;NCT02102789:Phase 3:Recruiting:No publish	No
iv	NCT00732836:Phase 1:Completed:No publish;;NCT00852228:Phase 2:Unknown status:No publish	No
disulfiram	NCT00742911:Phase 1:Completed:No publish	No
copper	NCT00742911:Phase 1:Completed:No publish	No
folfox6/cetuximab	NCT00743678:Phase 2:Completed:No publish	No
gc33	NCT00746317:Phase 1:Completed:No publish	No
imatinib	NCT00764595:Phase 2:Completed:No publish;;NCT00025415:Phase 1:Completed:No publish	Imatinib (伊马替尼):ABL1#p.A344V耐药性增加||ABL1#p.A350V耐药性增加||ABL1#p.A365V耐药性增加||ABL1#p.A366G耐药性增加||ABL1#p.A380T耐药性增加||ABL1#p.A397P耐药性增加||ABL1#p.A399T.||ABL1#p.A433T耐药性增加||KIT#p.A829P耐药性增加||KIT#p.C809G耐药性增加||ABL1#p.D276A耐药性增加||ABL1#p.D276G耐药性增加||ABL1#p.D363Y耐药性增加||KIT#p.D816G耐药性增加||KIT#p.D816H耐药性增加||KIT#p.D820G耐药性增加||KIT#p.D820Y敏感性增加||PDGFRA#p.D842V耐药性增加||KIT#p.D861H耐药性增加||ABL1#p.E255K耐药性增加||ABL1#p.E255V耐药性增加||ABL1#p.E258D耐药性增加||ABL1#p.E275K耐药性增加||ABL1#p.E275K.||ABL1#p.E275Q耐药性增加||ABL1#p.E279A.||ABL1#p.E279K耐药性增加||ABL1#p.E279Y.||ABL1#p.E279Z.||ABL1#p.E282G.||ABL1#p.E292Q耐药性增加||ABL1#p.E292V耐药性增加||ABL1#p.E352D.||ABL1#p.E352G.||ABL1#p.E355A耐药性增加||ABL1#p.E355D耐药性增加||ABL1#p.E355G耐药性增加||ABL1#p.E373K耐药性增加||ABL1#p.E450A耐药性增加||ABL1#p.E450G耐药性增加||ABL1#p.E450K耐药性增加||ABL1#p.E450V耐药性增加||ABL1#p.E453A耐药性增加||ABL1#p.E453D.||ABL1#p.E453G耐药性增加||ABL1#p.E453K耐药性增加||ABL1#p.E453V耐药性增加||ABL1#p.E459A耐药性增加||ABL1#p.E459G耐药性增加||ABL1#p.E459K耐药性增加||ABL1#p.E459V耐药性增加||KIT#p.E490K敏感性增加||ABL1#p.E494G.||ABL1#p.E507G耐药性增加||ABL1#p.F311I耐药性增加||ABL1#p.F311L耐药性增加||ABL1#p.F317C耐药性增加||ABL1#p.F317I耐药性增加||ABL1#p.F317L耐药性增加||ABL1#p.F317V耐药性增加||ABL1#p.F317V.||ABL1#p.F359C耐药性增加||ABL1#p.F359I耐药性增加||ABL1#p.F359L耐药性增加||ABL1#p.F359V耐药性增加||ABL1#p.F382L耐药性增加||ABL1#p.F486S耐药性增加||ABL1#p.G250E耐药性增加||ABL1#p.G250R耐药性增加||ABL1#p.G251D.||ABL1#p.G251E.||ABL1#p.G398R.||PDGFRA#p.G853D敏感性增加||ABL1#p.H396A耐药性增加||ABL1#p.H396P耐药性增加||ABL1#p.H396R耐药性增加||KIT#p.H697Y耐药性增加||PDGFRA#p.H845Y敏感性增加||ABL1#p.I242T耐药性增加||ABL1#p.I293V耐药性增加||ABL1#p.I418S耐药性增加||ABL1#p.I418V耐药性增加||ABL1#p.K247R耐药性增加||ABL1#p.K294RGG耐药性增加||ABL1#p.K378R.||ABL1#p.K419E.||KIT#p.K642E敏感性增加||KIT#p.K818_D820>N.||ABL1#p.L248V耐药性增加||ABL1#p.L273M耐药性增加||ABL1#p.L298V耐药性增加||ABL1#p.L324Q耐药性增加||ABL1#p.L340L.||ABL1#p.L364I耐药性增加||ABL1#p.L370P耐药性增加||ABL1#p.L384M耐药性增加||ABL1#p.L387F耐药性增加||ABL1#p.L387M耐药性增加||ABL1#p.L387V耐药性增加||KIT#p.L576P敏感性增加||KIT#p.L576P敏感性增加||ABL1#p.M237V耐药性增加||ABL1#p.M244V耐药性增加||ABL1#p.M343T耐药性增加||ABL1#p.M351K.||ABL1#p.M351T耐药性增加||ABL1#p.M388L耐药性增加||ABL1#p.M472I耐药性增加||ABL1#p.N368S.||ABL1#p.N374Y.||KIT#p.N680K耐药性增加||KIT#p.N822K耐药性增加||KIT#p.N822Y耐药性增加||ABL1#p.P310S.||ABL1#p.P480L耐药性增加||PDGFRA#p.P577S敏感性增加||ABL1#p.Q252E.||ABL1#p.Q252H耐药性增加||ABL1#p.Q252K.||ABL1#p.Q252M.||ABL1#p.Q252R耐药性增加||ABL1#p.R328M.||PDGFRA#p.R748G敏感性增加||PDGFRA#p.R841K敏感性增加||ABL1#p.S417F耐药性增加||ABL1#p.S417Y耐药性增加||ABL1#p.S438C耐药性增加||KIT#p.S709F.||KIT#p.S821F.||ABL1#p.T277A耐药性增加||ABL1#p.T315A耐药性增加||ABL1#p.T315I耐药性增加||KIT#p.T670I耐药性增加||PDGFRA#p.T674I耐药性增加||ABL1#p.V280A耐药性增加||ABL1#p.V289A耐药性增加||ABL1#p.V289I耐药性增加||ABL1#p.V299L耐药性增加||ABL1#p.V371A耐药性增加||ABL1#p.V379I耐药性增加||KIT#p.V559A敏感性增加||KIT#p.V559A敏感性增加||KIT#p.V559D敏感性增加||KIT#p.V559I耐药性增加||BRAF#p.V600E耐药性增加||KIT#p.V654A耐药性增加||ABL1#p.W261L耐药性增加||KIT#p.W557R敏感性增加||KIT#p.W557R敏感性增加||ABL1#p.Y253F耐药性增加||ABL1#p.Y253H耐药性增加||ABL1#p.Y320C耐药性增加||ABL1#p.Y342H耐药性增加||ABL1#p.Y393C耐药性增加||KIT#p.Y553N敏感性增加||KIT#p.Y553N敏感性增加||CSF1R#p.Y571D敏感性增加||KIT#p.Y823D耐药性增加
antiviral	NCT00768157:Phase 4:Unknown status:No publish	No
everolimus,	NCT00775073:Phase 2:Completed:No publish	No
orantinib	NCT00784290:Phase 1|Phase 2:Completed:No publish	No
sonovue-enhanced	NCT00788697:Phase 3:Completed:No publish	No
cf102	NCT00790218:Phase 1|Phase 2:Completed:No publish;;NCT02128958:Phase 2:Recruiting:No publish	No
songyou	NCT00805896:Phase 2:Unknown status:No publish	No
licartin	NCT00819650:Phase 2:Completed:No publish;;NCT00829465:Phase 4:Completed:No publish	No
brivanib	NCT00825955:Phase 3:Completed:No publish;;NCT00437424:Phase 1:Completed:No publish;;NCT01540461:Phase 1:Completed:No publish;;NCT00355238:Phase 2:Completed:No publish;;NCT03516071:Phase 2:Recruiting:No publish;;NCT03516071:Phase 2:Recruiting:No publish;;NCT00908752:Phase 3:Completed:No publish;;NCT00858871:Phase 3:Completed:No publish	No
lmwh	NCT00827554:Phase 2|Phase 3:Completed:No publish;;NCT02715492:Phase 3:Not yet recruiting:No publish	No
sonovue®	NCT00829413:Phase 3:Completed:No publish	No
adenosine	NCT00845689:Phase 1|Phase 2:Unknown status:No publish	No
yttrium-90	NCT00846131:Phase 1:Completed:Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, Habib A, Karp J, Al-Saden P, Lacouture M, Cotliar J, Abecassis M, Baker T, Salem R. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014 Aug;61(2):309-17. doi: 10.1016/j.jhep.2014.03.023. Epub 2014 Mar 27.	No
treatment	NCT00849264:Phase 2:Completed:No publish;;NCT00849264:Phase 2:Completed:No publish	No
adecatumumab	NCT00866944:Phase 2:Completed:No publish;;NCT00866944:Phase 2:Completed:No publish	No
amg	NCT00872014:Phase 2:Completed:No publish	No
tac	NCT00874406:Phase 4:Unknown status:No publish	No
lc	NCT00877071:Phase 2:Completed:No publish	No
aln-vsp02	NCT00882180:Phase 1:Completed:No publish	No
aeg35156	NCT00882869:Phase 1|Phase 2:Completed:No publish	No
panitumumab+folfox-4	NCT00885885:Phase 2:Completed:No publish	No
panitumumab+folfiri	NCT00885885:Phase 2:Completed:No publish	No
foretinib	NCT00920192:Phase 1:Completed:No publish	Foretinib:ABL1#p.V299L敏感性增加
fostamatinib	NCT00923481:Phase 2:Completed:No publish	No
sorafenib,	NCT00933816:Phase 1|Phase 2:Completed:No publish;;NCT01131689:Phase 1:Completed:No publish	No
gemcitabine	NCT00941967:Phase 2:Unknown status:No publish;;NCT00006010:Phase 2:Completed:Alberts SR, Reid JM, Morlan BW, Farr GH Jr, Camoriano JK, Johnson DB, Enger JR, Seay TE, Kim GP. Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial. Am J Clin Oncol. 2012 Oct;35(5):418-23.;;NCT00250822:Phase 2:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00304135:Phase 2|Phase 3:Completed:Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: F��d��ration Francophone de Canc��rologie Digestive 9902 phase II randomised study. Eur J Cancer. 2014 Nov;50(17):2975-82. doi: 10.1016/j.ejca.2014.08.013. Epub 2014 Sep 17.;;NCT00059865:Phase 1|Phase 2:Completed:Alberts SR, Sande JR, Foster NR, Quevedo FJ, McWilliams RR, Kugler JW, Fitch TR, Jaslowski AJ. Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943. J Gastrointest Cancer. 2007;38(2-4):87-94. doi: 10.1007/s12029-008-9037-8. Epub 2008 Nov 21.;;NCT01525069:Phase 1:Recruiting:No publish;;NCT00009893:Phase 2:Completed:Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA, Tschetter LK. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. Cancer. 2005 Jan 1;103(1):111-8.;;NCT01313377:Phase 3:Completed:No publish;;NCT00987766:Phase 1:Completed:No publish;;NCT00019513:Phase 1:Completed:No publish;;NCT02423239:Phase 1:Unknown status:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT00844688:Phase 2:Unknown status:No publish;;NCT00142467:Phase 2:Completed:No publish	No
4sc-201	NCT00943449:Phase 2:Completed:No publish	No
e7080	NCT00946153:Phase 1|Phase 2:Completed:No publish	No
sorafenib	NCT00949182:Phase 2:Completed:No publish;;NCT00867321:Phase 1|Phase 2:Completed:No publish;;NCT01324076:Phase 3:Unknown status:No publish;;NCT01182272:Phase 2:Unknown status:No publish;;NCT01075113:Phase 1:Active, not recruiting:No publish;;NCT01005199:Phase 2:Completed:No publish;;NCT02292173:Phase 1:Recruiting:No publish;;NCT00881751:Phase 2:Completed:No publish;;NCT00875615:Phase 2:Completed:No publish;;NCT01011010:Phase 1:Completed:No publish;;NCT01075555:Phase 3:Completed:No publish;;NCT00941967:Phase 2:Unknown status:No publish;;NCT03037437:Phase 2:Recruiting:No publish;;NCT00997022:Phase 1:Completed:No publish;;NCT01754987:Phase 1|Phase 2:Completed:No publish;;NCT00813293:Phase 2:Active, not recruiting:No publish;;NCT01497444:Phase 1:Active, not recruiting:No publish;;NCT01932385:Phase 2|Phase 3:Completed:No publish;;NCT03164382:Phase 3:Recruiting:No publish;;NCT01042041:Phase 1:Completed:No publish;;NCT01033240:Phase 2:Completed:No publish;;NCT01624285:Phase 2:Active, not recruiting:No publish;;NCT00844168:Phase 1:Completed:No publish;;NCT01008566:Phase 1:Completed:No publish;;NCT03211416:Phase 1|Phase 2:Recruiting:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT01775501:Phase 2:Active, not recruiting:No publish;;NCT01306058:Phase 1|Phase 2:Completed:No publish;;NCT01666756:Phase 1:Active, not recruiting:No publish;;NCT02575339:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT01502410:Phase 2:Completed:No publish;;NCT00844883:Phase 2:Completed:No publish;;NCT00999843:Phase 1|Phase 2:Unknown status:No publish;;NCT01658878:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT03439891:Phase 2:Recruiting:No publish;;NCT00976170:Phase 1:Completed:No publish;;NCT01004978:Phase 3:Active, not recruiting:No publish;;NCT01015833:Phase 3:Active, not recruiting:No publish;;NCT00906373:Phase 2:Completed:No publish;;NCT02240433:Phase 1:Active, not recruiting:No publish;;NCT00872014:Phase 2:Completed:No publish;;NCT01214343:Phase 3:Unknown status:No publish;;NCT01214343:Phase 3:Unknown status:No publish;;NCT00712855:Phase 1:Completed:No publish;;NCT03412773:Phase 3:Recruiting:No publish;;NCT01498952:Phase 1:Completed:No publish;;NCT00105443:Phase 3:Completed:Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.;;NCT00892424:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT01203787:Phase 4:Completed:No publish;;NCT01203787:Phase 4:Completed:No publish;;NCT00044512:Phase 2:Completed:Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.;;NCT01008917:Phase 1:Completed:No publish;;NCT00108953:Phase 2:Completed:Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006 Sep 10;24(26):4293-300. Epub 2006 Aug 14.;;NCT00494299:Phase 3:Completed:Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011 Sep;47(14):2117-27. doi: 10.1016/j.ejca.2011.05.007.;;NCT03582618:Phase 2:Not yet recruiting:No publish;;NCT01232296:Phase 2:Completed:No publish;;NCT02988440:Phase 1:Recruiting:No publish;;NCT00956436:Phase 1:Completed:No publish;;NCT00398814:Phase 1:Completed:Preliminary results / Journal of Clinical Oncology, 2008 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 26, No 15S (May 20 Supplement), 2008: 16024;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT01988493:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT02560779:Phase 1|Phase 2:Recruiting:No publish;;NCT02400788:Phase 1|Phase 2:Completed:No publish;;NCT02279719:Phase 1|Phase 2:Recruiting:No publish;;NCT01271504:Phase 1|Phase 2:Completed:No publish;;NCT02645981:Phase 2|Phase 3:Recruiting:No publish;;NCT01906216:Phase 2|Phase 3:Recruiting:No publish;;NCT00768937:Phase 1|Phase 2:Completed:No publish;;NCT00882869:Phase 1|Phase 2:Completed:No publish;;NCT02129322:Phase 2:Not yet recruiting:No publish;;NCT02423239:Phase 1:Unknown status:No publish;;NCT02354898:Phase 1:Recruiting:No publish;;NCT03009461:Phase 2:Recruiting:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT03468231:Phase 3:Recruiting:No publish;;NCT01482442:Phase 3:Completed:No publish;;NCT01272557:Phase 2:Unknown status:No publish;;NCT03578874:Phase 2:Recruiting:No publish;;NCT02774187:Phase 3:Active, not recruiting:Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One. 2015 Mar 5;10(3):e0119312. doi: 10.1371/journal.pone.0119312. eCollection 2015.;;NCT03518502:Phase 4:Recruiting:Cabrera R, Pannu DS, Caridi J, Firpi RJ, Soldevila-Pico C, Morelli G, Clark V, Suman A, George TJ Jr, Nelson DR. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2011 Jul;34(2):205-13. doi: 10.1111/j.1365-2036.2011.04697.x. Epub 2011 May 23.;;NCT03434379:Phase 3:Recruiting:No publish;;NCT03298451:Phase 3:Recruiting:No publish;;NCT03236649:Phase 3:Not yet recruiting:No publish;;NCT02867280:Phase 3:Recruiting:No publish;;NCT02562755:Phase 3:Recruiting:No publish;;NCT02733809:Phase 4:Recruiting:No publish;;NCT02716766:Phase 2:Recruiting:No publish;;NCT02672488:Phase 2:Recruiting:No publish;;NCT01761266:Phase 3:Active, not recruiting:No publish;;NCT02576509:Phase 3:Active, not recruiting:No publish;;NCT02504983:Phase 4:Unknown status:Liang KH, Lin CL, Chen SF, Chiu CW, Yang PC, Chang ML, Lin CC, Sung KF, Yeh C, Hung CF, Chien RN, Yeh CT. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Pharmacogenomics. 2016 Mar;17(4):353-66. doi: 10.2217/pgs.15.179. Epub 2016 Feb 12.;;NCT02436902:Phase 3:Recruiting:No publish;;NCT02358395:Phase 1:Completed:No publish;;NCT02971696:Phase 3:Completed:No publish;;NCT02961998:Phase 4:Completed:No publish;;NCT02311205:Phase 2:Active, not recruiting:No publish;;NCT01840592:Phase 2:Active, not recruiting:No publish;;NCT00846131:Phase 1:Completed:Kulik L, Vouche M, Koppe S, Lewandowski RJ, Mulcahy MF, Ganger D, Habib A, Karp J, Al-Saden P, Lacouture M, Cotliar J, Abecassis M, Baker T, Salem R. Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol. 2014 Aug;61(2):309-17. doi: 10.1016/j.jhep.2014.03.023. Epub 2014 Mar 27.;;NCT02178358:Phase 2:Active, not recruiting:No publish;;NCT01915602:Phase 2:Completed:No publish;;NCT01903694:Phase 3:Completed:No publish;;NCT01903694:Phase 3:Completed:No publish;;NCT01897038:Phase 1:Completed:No publish;;NCT01605734:Phase 2:Unknown status:No publish;;NCT01507064:Phase 2:Completed:No publish;;NCT01409499:Phase 4:Unknown status:No publish;;NCT01357486:Phase 2:Completed:No publish;;NCT01357486:Phase 2:Completed:No publish;;NCT01308723:Phase 1:Completed:No publish;;NCT01258608:Phase 2:Completed:No publish;;NCT01246986:Phase 2:Active, not recruiting:No publish;;NCT01170104:Phase 2:Unknown status:No publish;;NCT01098760:Phase 4:Completed:No publish;;NCT01004003:Phase 2:Completed:No publish;;NCT00987935:Phase 2:Completed:No publish;;NCT00943449:Phase 2:Completed:No publish;;NCT00901901:Phase 3:Completed:No publish;;NCT00892658:Phase 1:Active, not recruiting:No publish;;NCT01265576:Phase 2:Unknown status:No publish;;NCT00858871:Phase 3:Completed:No publish;;NCT00855218:Phase 2:Completed:No publish;;NCT01259193:Phase 2:Unknown status:No publish;;NCT00844688:Phase 2:Unknown status:No publish;;NCT00823290:Phase 1:Unknown status:No publish;;NCT00752063:Phase 2:Unknown status:No publish;;NCT00703365:Phase 2:Completed:No publish;;NCT00619541:Phase 2:Completed:No publish;;NCT00492752:Phase 3:Completed:Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.;;NCT00490685:Phase 2:Completed:No publish;;NCT00478374:Phase 1:Completed:Dufour JF, Hoppe H, Heim MH, Helbling B, Maurhofer O, Szucs-Farkas Z, Kickuth R, Borner M, Candinas D, Saar B. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010;15(11):1198-204. doi: 10.1634/theoncologist.2010-0180. Epub 2010 Oct 29.;;NCT00464919:Phase 2:Completed:No publish	Sorafenib (索拉非尼):BRAF#p.D594G敏感性增加||KIT#p.D820E敏感性增加||FLT3#p.D835H耐药性增加||FLT3#p.D835H耐药性增加||FLT3#p.D835H耐药性增加||FLT3#p.D835Y耐药性增加||KIT#p.E490K敏感性增加||FLT3#p.F691L.||BRAF#p.G469E敏感性增加||KIT#p.K642E敏感性增加||KIT#p.L576P敏感性增加||ARAF#p.S214C敏感性增加||KIT#p.V559A敏感性增加||KIT#p.V559D敏感性增加||KIT#p.V560D敏感性增加||KIT#p.W557R敏感性增加||KIT#p.Y553N敏感性增加
biib022	NCT00956436:Phase 1:Completed:No publish	No
adefovir	NCT00960518:Phase 2:Unknown status:No publish	No
combretastatin	NCT00960557:Phase 1:Completed:No publish	No
gc33(ro5137382)	NCT00976170:Phase 1:Completed:No publish	No
cetuximab	NCT00980239:Phase 1:Completed:No publish;;NCT01564810:Phase 4:Unknown status:No publish;;NCT00397384:Phase 1:Completed:No publish;;NCT03493048:Phase 2:Recruiting:No publish;;NCT00153998:Phase 2:Completed:No publish;;NCT00153998:Phase 2:Completed:No publish;;NCT00153998:Phase 2:Completed:No publish;;NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT03319459:Phase 1:Recruiting:No publish;;NCT00142428:Phase 2:Completed:No publish;;NCT01836653:Phase 2:Completed:No publish;;NCT01802645:Phase 2:Recruiting:No publish;;NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	Afatinib + Cetuximab:EGFR#p.G719A敏感性增加||EGFR#p.G719C敏感性增加||EGFR#p.G719D敏感性增加||EGFR#p.G719S敏感性增加||EGFR#p.L747S敏感性增加||EGFR#p.L858R敏感性增加||EGFR#p.L861P敏感性增加||EGFR#p.L861Q敏感性增加||EGFR#p.L861R敏感性增加||EGFR#p.S768I敏感性增加||EGFR#p.T790M敏感性增加
temsirolimus	NCT00980460:Phase 3:Active, not recruiting:No publish;;NCT01010126:Phase 2:Completed:No publish;;NCT01687673:Phase 2:Active, not recruiting:No publish;;NCT01567930:Phase 2:Unknown status:No publish	Temsirolimus (替西罗莫司):TSC1#p.E636fs敏感性增加
pv-10	NCT00986661:Phase 1:Recruiting:No publish	No
azd8055	NCT00999882:Phase 1:Completed:No publish	No
bay73-4506	NCT01003015:Phase 2:Completed:Bruix J, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Wagner A, Bolondi L. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer. 2013 Nov;49(16):3412-9. doi: 10.1016/j.ejca.2013.05.028. Epub 2013 Jun 25.	No
bibf	NCT01004003:Phase 2:Completed:No publish;;NCT00987935:Phase 2:Completed:No publish	No
everolimus	NCT01005199:Phase 2:Completed:No publish;;NCT01642186:Phase 2:Active, not recruiting:No publish;;NCT02081755:Phase 4:Recruiting:No publish;;NCT01423708:Phase 2:Unknown status:No publish;;NCT01469572:Phase 1:Active, not recruiting:No publish;;NCT01488487:Phase 2:Completed:No publish;;NCT01035229:Phase 3:Completed:No publish;;NCT01035229:Phase 3:Completed:No publish	Everolimus (依维莫司):TSC1#p.E636fs敏感性增加||FGFR4#p.G388R敏感性降低||TSC1#p.W103X敏感性增加||TSC1#p.A307V敏感性增加||TSC2#P.E588K敏感性增加||MTOR#p.N1421D敏感性增加||MTOR#p.K1171R敏感性增加||MTOR#p.I1973F敏感性增加
mitomycin	NCT01011010:Phase 1:Completed:No publish;;NCT00003907:Phase 2:Completed:No publish;;NCT01042041:Phase 1:Completed:No publish;;NCT01004978:Phase 3:Active, not recruiting:No publish;;NCT01511146:Phase 2:Unknown status:No publish;;NCT02638857:Phase 1|Phase 2:Unknown status:No publish;;NCT00023868:Phase 3:Completed:No publish	No
cs-1008	NCT01033240:Phase 2:Completed:No publish	No
foflox4	NCT01035385:Phase 3:Unknown status:No publish	No
idarubicin	NCT01040559:Phase 1:Completed:No publish	No
eicosapentaenoic	NCT01070355:Phase 2:Completed:No publish	No
vorinostat	NCT01075113:Phase 1:Active, not recruiting:No publish;;NCT00537121:Phase 1:Completed:No publish	No
[f	NCT01075399:Phase 2:Completed:No publish	No
pravastatin	NCT01075555:Phase 3:Completed:No publish;;NCT03219372:Phase 2:Recruiting:No publish;;NCT01357486:Phase 2:Completed:No publish;;NCT01418729:Phase 2:Completed:No publish	No
telbivudine	NCT01102335:Phase 4:Unknown status:No publish	No
doxorubicin,	NCT01116635:Phase 1|Phase 2:Completed:No publish	No
ezn-2968	NCT01120288:Phase 1:Completed:No publish	No
188re-sss	NCT01126463:Phase 1:Recruiting:No publish	No
silybin	NCT01129570:Phase 1:Completed:No publish	No
pentoxifylline	NCT01149304:Phase 2:Completed:Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, Hass P, Wust P, Kropf S, Gademann G, Ricke J. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS One. 2014 Nov 13;9(11):e112731. doi: 10.1371/journal.pone.0112731. eCollection 2014.	No
ursodeoxycholic	NCT01149304:Phase 2:Completed:Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, Hass P, Wust P, Kropf S, Gademann G, Ricke J. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS One. 2014 Nov 13;9(11):e112731. doi: 10.1371/journal.pone.0112731. eCollection 2014.	No
enoxaparin	NCT01149304:Phase 2:Completed:Seidensticker M, Seidensticker R, Damm R, Mohnike K, Pech M, Sangro B, Hass P, Wust P, Kropf S, Gademann G, Ricke J. Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS One. 2014 Nov 13;9(11):e112731. doi: 10.1371/journal.pone.0112731. eCollection 2014.	No
sunitinib	NCT01164202:Phase 2|Phase 3:Completed:No publish;;NCT00514228:Phase 2:Completed:Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kov��cs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010;15(3):285-92. doi: 10.1634/theoncologist.2009-0316. Epub 2010 Mar 4.;;NCT00247676:Phase 2:Completed:No publish;;NCT00806663:Phase 2:Completed:No publish;;NCT02465060:Phase 2:Recruiting:No publish	Sunitinib (舒尼替尼):RET#p.C634W敏感性增加||FLT3#p.D835Y耐药性增加||FLT3#p.D835Y敏感性增加||FLT3#p.D835Y敏感性增加||PDGFRA#p.D842V耐药性增加||PDGFRA#p.D842V.||KIT#p.E490K敏感性增加||KIT#p.H697Y敏感性增加||KIT#p.H697Y敏感性增加||KIT#p.K642E敏感性增加||KIT#p.L576P敏感性增加||KIT#p.L576P敏感性增加||RET#p.M918T敏感性增加||KIT#p.N822K耐药性增加||KIT#p.V559A敏感性增加||KIT#p.V559D敏感性增加||BRAF#p.V600E耐药性增加||KIT#p.W557R敏感性增加||KIT#p.W557R敏感性增加||KIT#p.Y553N敏感性增加||KIT#p.Y553N敏感性增加||KIT#p.Y823D耐药性增加
placebo	NCT01164202:Phase 2|Phase 3:Completed:No publish;;NCT02029157:Phase 3:Completed:No publish;;NCT00845689:Phase 1|Phase 2:Unknown status:No publish;;NCT01640808:Phase 3:Unknown status:No publish;;NCT00575523:Phase 4:Completed:No publish;;NCT01562821:Phase 2:Completed:Shao YF, Yang JM, Chau GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E, Nivatvongs S, Lee PH. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg. 2006 Feb;191(2):245-9.;;NCT02435433:Phase 3:Recruiting:No publish;;NCT00105443:Phase 3:Completed:Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.;;NCT00707681:Phase 2:Unknown status:No publish;;NCT00494299:Phase 3:Completed:Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011 Sep;47(14):2117-27. doi: 10.1016/j.ejca.2011.05.007.;;NCT03326791:Phase 2:Recruiting:No publish;;NCT01908426:Phase 3:Active, not recruiting:No publish;;NCT00692770:Phase 3:Completed:Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre MA, Meinhardt G, Llovet JM; STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015 Oct;16(13):1344-54. doi: 10.1016/S1470-2045(15)00198-9. Epub 2015 Sep 8.;;NCT00538850:Phase 3:Completed:Rauck R, Reynolds L, Geach J, Bull J, Stearns L, Scherlis M, Parikh N, Dillaha L. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012 May;28(5):859-70. doi: 10.1185/03007995.2012.683111. Epub 2012 May 2.;;NCT03515369:Phase 4:Not yet recruiting:No publish;;NCT03219372:Phase 2:Recruiting:No publish;;NCT03235167:Phase 1:Not yet recruiting:No publish;;NCT03062358:Phase 3:Recruiting:No publish;;NCT03024684:Phase 4:Recruiting:No publish;;NCT02799212:Phase 3:Recruiting:No publish;;NCT02702401:Phase 3:Active, not recruiting:No publish;;NCT03275376:Phase 2:Recruiting:No publish;;NCT02528643:Phase 2:Active, not recruiting:No publish;;NCT02329860:Phase 3:Active, not recruiting:No publish;;NCT02178358:Phase 2:Active, not recruiting:No publish;;NCT02128958:Phase 2:Recruiting:No publish;;NCT01774344:Phase 3:Active, not recruiting:Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.;;NCT01755767:Phase 3:Completed:No publish;;NCT01507168:Phase 2:Completed:No publish;;NCT00080236:Phase 2:Completed:No publish;;NCT01287585:Phase 3:Completed:No publish;;NCT01258608:Phase 2:Completed:No publish;;NCT00988741:Phase 2:Completed:No publish;;NCT00901901:Phase 3:Completed:No publish;;NCT01265576:Phase 2:Unknown status:No publish;;NCT00858871:Phase 3:Completed:No publish;;NCT00855218:Phase 2:Completed:No publish;;NCT00805896:Phase 2:Unknown status:No publish;;NCT00492752:Phase 3:Completed:Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.;;NCT01070355:Phase 2:Completed:No publish	No
jx-594	NCT01171651:Phase 2:Completed:No publish	No
cudc-101	NCT01171924:Phase 1:Completed:No publish	No
cc-223	NCT01177397:Phase 1|Phase 2:Completed:No publish	No
maa	NCT01186263:Phase 2:Completed:No publish	No
diagnostic	NCT01186263:Phase 2:Completed:No publish	No
bay86-9766	NCT01204177:Phase 2:Completed:No publish	No
[f-18]	NCT01213030:Phase 1|Phase 2:Completed:No publish;;NCT01213030:Phase 1|Phase 2:Completed:No publish;;NCT00884520:Early Phase 1:Completed:No publish	No
dovitinib	NCT01232296:Phase 2:Completed:No publish	Dovitinib:FGFR2#p.E566G耐药性增加||FGFR2#p.I548V耐药性增加||FGFR2#p.K660E耐药性增加||FGFR2#p.L618M耐药性增加||FGFR2#p.M536I耐药性增加||FGFR2#p.M538I耐药性增加||FGFR2#p.V565I耐药性增加
cinobufacin	NCT01236690:Phase 2:Unknown status:No publish	No
torisel	NCT01251458:Phase 1|Phase 2:Completed:No publish	No
mapatumumab	NCT01258608:Phase 2:Completed:No publish	No
panitumumab,	NCT01260415:Phase 2:Completed:No publish	No
clevudine,	NCT01263002:Phase 4:Completed:No publish	No
bavituximab	NCT01264705:Phase 1|Phase 2:Unknown status:No publish;;NCT03519997:Phase 2:Recruiting:No publish	No
vt-122	NCT01265576:Phase 2:Unknown status:No publish	No
ag-013736	NCT01273662:Phase 2:Completed:No publish	No
propranolol	NCT01298284:Phase 4:Unknown status:No publish;;NCT01970748:Phase 4:Unknown status:No publish;;NCT01451658:Phase 4:Unknown status:No publish	No
trc	NCT01306058:Phase 1|Phase 2:Completed:No publish	No
sb	NCT01308645:Phase 2:Unknown status:No publish	No
ro5323441	NCT01308723:Phase 1:Completed:No publish	No
cetuximab;	NCT01322178:Phase 2:Unknown status:No publish	No
doxorubicin-eluting	NCT01324076:Phase 3:Unknown status:No publish;;NCT01004978:Phase 3:Active, not recruiting:No publish	No
axitinib	NCT01334112:Phase 2:Active, not recruiting:No publish;;NCT03289533:Phase 1:Recruiting:No publish;;NCT01352728:Phase 2:Completed:No publish	Axitinib (阿昔替尼):ABL1#p.T315I敏感性增加
paclitaxel	NCT01347424:Phase 2:Unknown status:No publish;;NCT01347424:Phase 2:Unknown status:No publish;;NCT00002854:Phase 1:Completed:No publish;;NCT01953926:Phase 2:Recruiting:No publish;;NCT00508326:Phase 1:Completed:No publish	No
dendritic	NCT01348256:Phase 2:Recruiting:No publish	No
other	NCT01348412:Phase 2:Completed:No publish	No
pd-0332991	NCT01356628:Phase 2:Active, not recruiting:No publish	No
m-tor	NCT01374750:Phase 2:Completed:No publish	No
trc105	NCT01375569:Phase 2:Completed:No publish;;NCT02560779:Phase 1|Phase 2:Recruiting:No publish	No
11c-choline	NCT01377220:Phase 2:Unknown status:No publish	No
tace-deb	NCT01381211:Phase 2:Unknown status:No publish	No
90y-re	NCT01381211:Phase 2:Unknown status:No publish	No
folic	NCT01384994:Phase 2:Unknown status:No publish	No
panitumumab	NCT01384994:Phase 2:Unknown status:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT01226719:Phase 2:Completed:No publish;;NCT02885753:Phase 3:Recruiting:No publish;;NCT03069950:Phase 2:Recruiting:No publish	Panitumumab + Dabrafenib + Trametinib:BRAF#p.V600E敏感性增加
oxaliplatin,	NCT01387295:Phase 2:Unknown status:No publish;;NCT01387373:Phase 2:Unknown status:No publish;;NCT03164655:Phase 2:Not yet recruiting:No publish	No
n-acetylcystein	NCT01394497:Phase 2:Completed:D'Amico F, Vitale A, Piovan D, Bertacco A, Ramirez Morales R, Chiara Frigo A, Bassi D, Bonsignore P, Gringeri E, Valmasoni M, Garbo G, Lodo E, D'Amico FE, Scopelliti M, Carraro A, Gambato M, Brolese A, Zanus G, Neri D, Cillo U. Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. Liver Transpl. 2013 Feb;19(2):135-44. doi: 10.1002/lt.23527. Epub 2012 Sep 26.	No
18f-fluoromethylcholine	NCT01395030:Phase 2:Active, not recruiting:No publish	No
opb-31121	NCT01406574:Phase 1|Phase 2:Completed:No publish;;NCT01406574:Phase 1|Phase 2:Completed:No publish	No
nhs-il-12	NCT01417546:Phase 1:Recruiting:No publish	No
akt	NCT01425879:Phase 2:Completed:No publish	non-allosteric AKT 抑制剂:AKT1#p.E17K敏感性增加
sox	NCT01429961:Phase 2:Unknown status:No publish	No
trabectedin	NCT01453283:Phase 1:Completed:No publish	No
177lu-dota-tate	NCT01456078:Phase 2:Recruiting:No publish	No
pasireotide	NCT01469572:Phase 1:Active, not recruiting:No publish;;NCT01488487:Phase 2:Completed:No publish	No
sir-sphere	NCT01482442:Phase 3:Completed:No publish	No
tyroserleutide	NCT01489566:Phase 3:Unknown status:No publish	No
the	NCT01489566:Phase 3:Unknown status:No publish	No
hypoxia-activated	NCT01497444:Phase 1:Active, not recruiting:No publish	No
medi-573	NCT01498952:Phase 1:Completed:No publish	No
ro5137382	NCT01507168:Phase 2:Completed:No publish	No
activated	NCT01562821:Phase 2:Completed:Shao YF, Yang JM, Chau GY, Sirivatanauksorn Y, Zhong SX, Erhardtsen E, Nivatvongs S, Lee PH. Safety and hemostatic effect of recombinant activated factor VII in cirrhotic patients undergoing partial hepatectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Am J Surg. 2006 Feb;191(2):245-9.	No
gadoxetic	NCT01575574:Phase 4:Completed:No publish	No
nintedanib	NCT01594125:Phase 1:Completed:No publish;;NCT01594125:Phase 1:Completed:No publish;;NCT01594125:Phase 1:Completed:No publish	No
immu-132	NCT01631552:Phase 1|Phase 2:Active, not recruiting:No publish	No
bevacizumab,	NCT01632722:Phase 2:Completed:No publish	No
romidepsin	NCT01638533:Phase 1:Recruiting:No publish	No
xenetix-ct	NCT01639703:Phase 4:Completed:No publish	No
nik-333(peretinoin)	NCT01640808:Phase 3:Unknown status:No publish	No
letrozole	NCT01642186:Phase 2:Active, not recruiting:No publish	No
combination	NCT01642186:Phase 2:Active, not recruiting:No publish	No
tranexamic	NCT01655641:Phase 2|Phase 3:Unknown status:Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007 May 31;356(22):2301-11. Review.	No
ipilimumab	NCT01658878:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT03203304:Phase 1:Recruiting:No publish;;NCT03222076:Phase 2:Recruiting:No publish	Ipilimumab (易普利姆玛):BRAF#p.V600E敏感性增加||BRAF#p.V600K敏感性增加||BRAF#p.V600R敏感性增加
cabozantinib	NCT01658878:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT03299946:Phase 1:Recruiting:No publish;;NCT01908426:Phase 3:Active, not recruiting:No publish;;NCT02867592:Phase 2:Recruiting:No publish;;NCT03539822:Phase 1:Not yet recruiting:No publish;;NCT03586973:Phase 2:Recruiting:No publish	Cabozantinib (卡博替尼):RET#p.C634W敏感性增加||ROS1#p.G2032R敏感性增加||RET#p.M918T敏感性增加||ABL1#p.V299L敏感性增加
sta-9090	NCT01665937:Phase 1:Completed:No publish	No
interferon-alpha	NCT01681446:Phase 3:Recruiting:No publish	No
sorafenib:	NCT01687673:Phase 2:Active, not recruiting:No publish	No
phase	NCT01721941:Phase 1:Unknown status:No publish;;NCT01721941:Phase 1:Unknown status:No publish;;NCT01721941:Phase 1:Unknown status:No publish;;NCT01721941:Phase 1:Unknown status:No publish;;NCT03475953:Phase 1|Phase 2:Recruiting:No publish;;NCT03475953:Phase 1|Phase 2:Recruiting:No publish;;NCT03475953:Phase 1|Phase 2:Recruiting:No publish;;NCT03475953:Phase 1|Phase 2:Recruiting:No publish	No
mm-141	NCT01733004:Phase 1:Completed:No publish	No
tasquinimod	NCT01743469:Phase 2:Completed:No publish	No
suranix	NCT01747642:Phase 2|Phase 3:Unknown status:No publish	No
sgi-110	NCT01752933:Phase 2:Completed:No publish	No
ascorbic	NCT01754987:Phase 1|Phase 2:Completed:No publish	No
tivantinib	NCT01755767:Phase 3:Completed:No publish	No
6,8-bis(benzylthio)octanoic	NCT01766219:Phase 1|Phase 2:Active, not recruiting:No publish	No
huaier	NCT01770431:Phase 4:Completed:No publish	No
regorafenib	NCT01774344:Phase 3:Active, not recruiting:Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26.	No
g-202	NCT01777594:Phase 2:Completed:No publish	No
chlorhexidine	NCT01782573:Phase 4:Completed:No publish	No
meglumine	NCT01806740:Phase 4:Active, not recruiting:No publish	No
mct/lct	NCT01819961:Phase 4:Unknown status:No publish;;NCT01819961:Phase 4:Unknown status:No publish	No
cisplatin、fluorouracil	NCT01834963:Phase 2:Recruiting:No publish	No
tivozanib	NCT01835223:Phase 1|Phase 2:Active, not recruiting:No publish	No
l-ohp	NCT01836653:Phase 2:Completed:No publish	No
l-lv	NCT01836653:Phase 2:Completed:No publish	No
azd9150	NCT01839604:Phase 1:Completed:No publish	No
hia	NCT01839877:Phase 2:Active, not recruiting:No publish	No
tremelimumab	NCT01853618:Phase 1:Active, not recruiting:No publish;;NCT02754856:Phase 1:Recruiting:No publish;;NCT03298451:Phase 3:Recruiting:No publish;;NCT03298451:Phase 3:Recruiting:No publish	No
lipiodol	NCT01877187:Phase 2:Active, not recruiting:No publish;;NCT01959061:Phase 4:Recruiting:No publish;;NCT02638857:Phase 1|Phase 2:Unknown status:No publish;;NCT02755311:Phase 3:Unknown status:No publish;;NCT02631499:Phase 4:Not yet recruiting:No publish	No
onartuzumab	NCT01897038:Phase 1:Completed:No publish	No
immuncell-lc	NCT01897610:Phase 2:Completed:No publish	No
ixazomib	NCT01912222:Phase 1:Completed:No publish	No
refametinib	NCT01915589:Phase 2:Completed:No publish;;NCT01915602:Phase 2:Completed:No publish	No
urea-based	NCT01934829:Phase 2:Completed:Bosch FX, Ribes J, Cléries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005 May;9(2):191-211, v. Review.	No
colchicine	NCT01935700:Phase 2:Recruiting:No publish	No
aspirin	NCT01936233:Phase 3:Unknown status:No publish	No
neratinib	NCT01953926:Phase 2:Recruiting:No publish	Neratinib (来那替尼):ERBB2#p.D769H敏感性增加||ERBB2#p.D769Y敏感性增加||ERBB2#p.G309A敏感性增加||ERBB2#p.K753E敏感性增加||ERBB2#p.L755S敏感性增加||ERBB2#p.R896C敏感性增加||ERBB2#p.V777L敏感性增加||ERBB2#p.V842I敏感性增加
fulvestrant	NCT01953926:Phase 2:Recruiting:No publish	No
raltitrexed	NCT01959061:Phase 4:Recruiting:No publish;;NCT01348412:Phase 2:Completed:No publish	No
oxaliplatin;capecitabine	NCT01962376:Phase 4:Unknown status:No publish	No
oxaliplatin;capecitabine;bevacizumab	NCT01962376:Phase 4:Unknown status:No publish	No
ethiodized	NCT01966133:Phase 3:Active, not recruiting:No publish	No
aldesleukin	NCT01967823:Phase 2:Recruiting:No publish;;NCT01174121:Phase 2:Recruiting:No publish	No
fludarabine	NCT01967823:Phase 2:Recruiting:No publish;;NCT03084380:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT01174121:Phase 2:Recruiting:No publish;;NCT02905188:Phase 1:Not yet recruiting:No publish	No
5-fu	NCT01972503:Phase 4:Unknown status:No publish;;NCT01384994:Phase 2:Unknown status:No publish;;NCT00557557:Phase 1:Completed:No publish;;NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT01836653:Phase 2:Completed:No publish;;NCT00803647:Phase 2:Completed:No publish;;NCT01695772:Phase 4:Completed:No publish;;NCT01802645:Phase 2:Recruiting:No publish	No
hcq	NCT02013778:Phase 1|Phase 2:Recruiting:No publish	No
capecitabine	NCT02013830:Phase 2:Completed:No publish;;NCT00483405:Phase 2:Completed:Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH. Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res. 2011 May;4(3):78-83.;;NCT00076609:Phase 1|Phase 2:Completed:No publish;;NCT00363584:Phase 3:Completed:No publish;;NCT02576964:Phase 2:Completed:No publish;;NCT00073905:Phase 2:Completed:Koeberle D, Saletti P, Borner M, Gerber D, Dietrich D, Caspar CB, Mingrone W, Beretta K, Strasser F, Ruhstaller T, Mora O, Herrmann R; Swiss Group for Clinical Cancer Research. Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2008 Aug 1;26(22):3702-8. doi: 10.1200/JCO.2008.16.5704.;;NCT00486356:Phase 1:Completed:No publish;;NCT00021047:Phase 1|Phase 2:Completed:No publish;;NCT02042443:Phase 2:Completed:No publish;;NCT00997685:Phase 2:Unknown status:No publish;;NCT00156975:Phase 3:Unknown status:No publish;;NCT00003867:Phase 1:Unknown status:Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34.;;NCT00010023:Phase 1:Completed:Chen TT, Ryan T, Potmesil M, et al.: Cisplatin/capecitabine: tolerance and activity in patients with upper gastrointestinal cancers. [Abstract] American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium, 22-24 January 2004, San Francisco, CA. A-53, 2004.;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT00561522:Phase 2|Phase 3:Unknown status:No publish;;NCT03578874:Phase 2:Recruiting:No publish;;NCT03114085:Phase 2:Not yet recruiting:No publish;;NCT02716766:Phase 2:Recruiting:No publish;;NCT00464295:Phase 2:Completed:No publish;;NCT01167049:Phase 2:Unknown status:No publish;;NCT01022541:Phase 2:Completed:No publish;;NCT00482222:Phase 3:Unknown status:No publish;;NCT00026234:Phase 2:Completed:No publish	No
bevacizumab	NCT02013830:Phase 2:Completed:No publish;;NCT00605722:Phase 2:Completed:No publish;;NCT00467194:Phase 1:Completed:No publish;;NCT00576199:Phase 2:Completed:No publish;;NCT00242502:Phase 2:Completed:No publish;;NCT01180959:Phase 2:Active, not recruiting:No publish;;NCT00980239:Phase 1:Completed:No publish;;NCT01763450:Phase 2:Unknown status:No publish;;NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT00200200:Phase 2:Active, not recruiting:No publish;;NCT03434379:Phase 3:Recruiting:No publish;;NCT03382886:Phase 1:Recruiting:No publish;;NCT00287222:Phase 2:Completed:No publish;;NCT00162669:Phase 2:Unknown status:No publish;;NCT00142467:Phase 2:Completed:No publish;;NCT01836653:Phase 2:Completed:No publish;;NCT01695772:Phase 4:Completed:No publish;;NCT01022541:Phase 2:Completed:No publish;;NCT02885753:Phase 3:Recruiting:No publish;;NCT01802645:Phase 2:Recruiting:No publish	No
dalantercept	NCT02024087:Phase 1|Phase 2:Completed:No publish	No
zavedos®	NCT02028949:Phase 1:Completed:No publish	No
arq197	NCT02029157:Phase 3:Completed:No publish	No
dexmedetomidine	NCT02044224:Phase 4:Completed:No publish;;NCT02016391:Phase 4:Completed:No publish	No
omp-54f28	NCT02069145:Phase 1:Completed:No publish	No
18f-	NCT02074202:Phase 3:Unknown status:No publish;;NCT02074202:Phase 3:Unknown status:No publish	No
tacrolimus	NCT02081755:Phase 4:Recruiting:No publish	No
myfortic	NCT02081755:Phase 4:Recruiting:No publish	No
cellcept	NCT02081755:Phase 4:Recruiting:No publish	No
imuran	NCT02081755:Phase 4:Recruiting:No publish	No
ly2875358	NCT02082210:Phase 1|Phase 2:Completed:No publish	No
capecitabine,	NCT02086656:Phase 2:Active, not recruiting:No publish	No
n-acetylcysteine	NCT02094625:Phase 1:Recruiting:No publish	No
adi-peg	NCT02101593:Phase 1:Completed:No publish;;NCT02006030:Phase 2:Completed:No publish;;NCT02102022:Phase 1|Phase 2:Recruiting:No publish;;NCT02029690:Phase 1:Active, not recruiting:No publish;;NCT01287585:Phase 3:Completed:No publish;;NCT00056992:Phase 2:Completed:No publish	No
dummy	NCT02112656:Phase 3:Recruiting:No publish	No
msc2156119j	NCT02115373:Phase 1|Phase 2:Completed:No publish;;NCT01988493:Phase 1|Phase 2:Active, not recruiting:No publish	No
s-1	NCT02129322:Phase 2:Not yet recruiting:No publish;;NCT01533324:Phase 2:Unknown status:No publish;;NCT01997957:Phase 4:Unknown status:No publish;;NCT02634502:Phase 2:Recruiting:No publish	No
delayed	NCT02145559:Phase 1:Active, not recruiting:No publish	No
sirolimus	NCT02145559:Phase 1:Active, not recruiting:No publish;;NCT00328770:Phase 2|Phase 3:Completed:No publish;;NCT01522820:Phase 1:Completed:No publish;;NCT01374750:Phase 2:Completed:No publish;;NCT00355862:Phase 3:Completed:No publish;;NCT00554125:Phase 3:Unknown status:No publish	Cetuximab + Sirolimus:EGFR#p.P753S敏感性增加
lde225	NCT02151864:Phase 1:Active, not recruiting:No publish	No
folfoxiri	NCT02162563:Phase 3:Recruiting:No publish;;NCT02063529:Phase 2:Recruiting:No publish;;NCT02063529:Phase 2:Recruiting:No publish;;NCT02350530:Phase 2:Recruiting:No publish;;NCT02350530:Phase 2:Recruiting:No publish;;NCT03487939:Phase 2:Not yet recruiting:No publish;;NCT03401294:Phase 2:Not yet recruiting:No publish	No
folfox/	NCT02162563:Phase 3:Recruiting:No publish;;NCT02162563:Phase 3:Recruiting:No publish	No
vitamin	NCT02172651:Early Phase 1:Recruiting:No publish;;NCT02779465:Phase 4:Not yet recruiting:Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31.	No
tirapazamine	NCT02174549:Phase 1|Phase 2:Recruiting:No publish;;NCT03145558:Phase 2:Recruiting:No publish	No
sevoflurane	NCT02174575:Phase 4:Unknown status:No publish	No
desflurane	NCT02174575:Phase 4:Unknown status:No publish	No
mk-3475	NCT02178722:Phase 1|Phase 2:Active, not recruiting:No publish	No
incb024360	NCT02178722:Phase 1|Phase 2:Active, not recruiting:No publish	No
lyso-thermosensitive	NCT02181075:Phase 1:Completed:No publish;;NCT00093444:Phase 1:Completed:No publish	No
tkm-080301	NCT02191878:Phase 1|Phase 2:Completed:No publish;;NCT01437007:Phase 1:Completed:No publish	No
ganciclovir	NCT02202564:Phase 2:Completed:No publish	No
adv-tk	NCT02202564:Phase 2:Completed:No publish;;NCT03313596:Phase 3:Recruiting:No publish	No
peprostat	NCT02204930:Phase 1:Completed:No publish	No
donafenib(200mg)	NCT02229071:Phase 1|Phase 2:Completed:No publish	No
donafenib(300mg)	NCT02229071:Phase 1|Phase 2:Completed:No publish	No
enmd-2076	NCT02234986:Phase 2:Active, not recruiting:No publish	No
ly2157299	NCT02240433:Phase 1:Active, not recruiting:No publish;;NCT02178358:Phase 2:Active, not recruiting:No publish;;NCT01246986:Phase 2:Active, not recruiting:No publish	No
oral	NCT02240771:Phase 2|Phase 3:Unknown status:No publish;;NCT01438450:Phase 2|Phase 3:Unknown status:No publish;;NCT00168987:Phase 4:Completed:No publish;;NCT02856126:Phase 3:Recruiting:No publish;;NCT02210182:Phase 1:Completed:No publish	No
cidan	NCT02253511:Phase 4:Unknown status:No publish	No
stm	NCT02262455:Phase 1:Completed:No publish	No
bbi503	NCT02279719:Phase 1|Phase 2:Recruiting:No publish;;NCT02354898:Phase 1:Recruiting:No publish;;NCT02232633:Phase 2:Active, not recruiting:No publish	No
bbi608	NCT02279719:Phase 1|Phase 2:Recruiting:No publish;;NCT02358395:Phase 1:Completed:No publish	No
nucleoside	NCT02281266:Phase 4:Not yet recruiting:No publish	No
thymalfasin	NCT02281266:Phase 4:Not yet recruiting:No publish;;NCT00082082:Phase 2:Completed:No publish	No
trametinib	NCT02292173:Phase 1:Recruiting:No publish;;NCT02042443:Phase 2:Completed:No publish;;NCT02070549:Phase 1:Recruiting:No publish;;NCT02465060:Phase 2:Recruiting:No publish	Panitumumab + Dabrafenib + Trametinib:BRAF#p.V600E敏感性增加
pirarubicin,mitomycin	NCT02301091:Phase 3:Recruiting:No publish	No
tas-102	NCT02301104:Phase 1:Completed:No publish	No
artesunate	NCT02304289:Phase 1:Completed:No publish	No
tenofovir	NCT02308319:Phase 4:Not yet recruiting:No publish	No
pf-04518600	NCT02315066:Phase 1:Recruiting:No publish;;NCT02315066:Phase 1:Recruiting:No publish	No
decitabine	NCT02316028:Phase 1|Phase 2:Completed:No publish	No
omega-3	NCT02321202:Phase 4:Completed:No publish	No
structolipid	NCT02321202:Phase 4:Completed:No publish	No
egm	NCT02338297:Phase 3:Unknown status:No publish	No
pva	NCT02338297:Phase 3:Unknown status:No publish	No
herceptin	NCT02380131:Phase 4:Unknown status:No publish	No
rsifn-co	NCT02387307:Phase 1:Unknown status:No publish	No
xihuang	NCT02399033:Phase 4:Recruiting:No publish	No
resminostat	NCT02400788:Phase 1|Phase 2:Completed:No publish	No
jnj-42756493	NCT02421185:Phase 1:Recruiting:No publish	No
dexanabinol	NCT02423239:Phase 1:Unknown status:No publish	No
galunisertib	NCT02423343:Phase 1|Phase 2:Recruiting:No publish	No
5-fluorouracil/leucovorin	NCT02426450:Phase 2:Unknown status:No publish	No
ramucirumab	NCT02435433:Phase 3:Recruiting:No publish;;NCT02082210:Phase 1|Phase 2:Completed:No publish;;NCT02572687:Phase 1:Active, not recruiting:No publish;;NCT01246986:Phase 2:Active, not recruiting:No publish	No
thalidomine	NCT02447679:Phase 2:Completed:No publish	No
tegafur-uracil	NCT02447679:Phase 2:Completed:No publish	No
raltitrexed-based	NCT02453490:Phase 3:Recruiting:No publish	No
5-fluorouracil-based	NCT02453490:Phase 3:Recruiting:No publish	No
adavosertib	NCT02465060:Phase 2:Recruiting:No publish	No
afatinib	NCT02465060:Phase 2:Recruiting:No publish	Afatinib + Cetuximab:EGFR#p.G719A敏感性增加||EGFR#p.G719C敏感性增加||EGFR#p.G719D敏感性增加||EGFR#p.G719S敏感性增加||EGFR#p.L747S敏感性增加||EGFR#p.L858R敏感性增加||EGFR#p.L861P敏感性增加||EGFR#p.L861Q敏感性增加||EGFR#p.L861R敏感性增加||EGFR#p.S768I敏感性增加||EGFR#p.T790M敏感性增加
binimetinib	NCT02465060:Phase 2:Recruiting:No publish	No
capivasertib	NCT02465060:Phase 2:Recruiting:No publish	No
crizotinib	NCT02465060:Phase 2:Recruiting:No publish	Crizotinib (克唑替尼):ALK#p.A348D敏感性增加||ALK#p.C1156Y耐药性增加||ALK#p.C1156Y耐药性增加||ALK#p.F1174L耐药性增加||ALK#p.F1174L耐药性增加||ALK#p.F1245C敏感性增加||ALK#p.F856S敏感性增加||ALK#p.G1128A敏感性增加||ALK#p.G1202R耐药性增加||ALK#p.G1269A耐药性增加||ROS1#p.G2032R耐药性增加||MET#p.H1112L敏感性增加||MET#p.H1112R敏感性增加||ALK#p.I1171N敏感性增加||ALK#p.I1171T耐药性增加||ALK#p.L1152R耐药性增加||ALK#p.L1196M耐药性增加||ALK#p.L1196M耐药性增加||ALK#p.L1198F敏感性增加||MET#p.M1268T敏感性增加||ALK#p.R1192P敏感性增加||ALK#p.R1275Q敏感性增加||MET#p.R988C敏感性增加||ALK#p.S1206Y耐药性增加||MET#p.T1010I敏感性增加||MET#p.V1110I敏感性增加||ABL1#p.V299L敏感性增加
dabrafenib	NCT02465060:Phase 2:Recruiting:No publish	Panitumumab + Dabrafenib + Trametinib:BRAF#p.V600E敏感性增加
defactinib	NCT02465060:Phase 2:Recruiting:No publish	No
fgfr	NCT02465060:Phase 2:Recruiting:No publish	FGFR 抑制剂:FGFR2#p.K660N敏感性增加||FGFR2#p.N550K敏感性增加||FGFR2#p.S252W敏感性增加||FGFR2#p.S320C敏感性增加||FGFR3#p.V555M耐药性增加||FGFR2#p.V565I敏感性增加||FGFR2#p.W290C敏感性增加||FGFR3#p.Y373C敏感性增加
larotrectinib	NCT02465060:Phase 2:Recruiting:No publish	No
osimertinib	NCT02465060:Phase 2:Recruiting:No publish	Osimertinib (奥希替尼):EGFR#p.L858R敏感性增加||EGFR#p.T790M敏感性增加
palbociclib	NCT02465060:Phase 2:Recruiting:No publish	No
pi3k-beta	NCT02465060:Phase 2:Recruiting:No publish	No
sapanisertib	NCT02465060:Phase 2:Recruiting:No publish	No
taselisib	NCT02465060:Phase 2:Recruiting:No publish	No
vismodegib	NCT02465060:Phase 2:Recruiting:No publish;;NCT01546519:Phase 1:Completed:No publish	Vismodegib (维莫德吉):SMO#p.D473G耐药性增加||SMO#p.D473H耐药性增加||SMO#p.D473H耐药性增加||SMO#p.G497W耐药性增加||SMO#p.L412F耐药性增加||SMO#p.Q477E耐药性增加||SMO#p.W281C耐药性增加||SMO#p.W535L耐药性增加
in111-pentetréotide	NCT02465112:Phase 3:Recruiting:No publish	No
[18f]	NCT02471313:Phase 2:Completed:No publish	No
lv5fu2	NCT02494973:Phase 2|Phase 3:Recruiting:No publish	No
blu-554	NCT02508467:Phase 1:Recruiting:No publish	No
tae	NCT02509169:Phase 2:Unknown status:No publish	No
talimogene	NCT02509507:Phase 1:Recruiting:No publish	No
lee011	NCT02524119:Phase 2:Recruiting:No publish	No
liposomal	NCT02527772:Phase 2|Phase 3:Active, not recruiting:Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanus G, Donach M, Farina M, Zovato S, Pastorelli D. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer. 2011 Jan 1;117(1):125-33. doi: 10.1002/cncr.25578. Epub 2010 Aug 31.|Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26.;;NCT02262455:Phase 1:Completed:No publish;;NCT00507962:Phase 1:Completed:No publish	No
oxy111a	NCT02528526:Phase 1|Phase 2:Unknown status:No publish	No
gemox	NCT02534337:Phase 2|Phase 3:Unknown status:No publish	No
cefazolin	NCT02534961:Phase 4:Unknown status:No publish	No
oxaliplatin	NCT02557503:Phase 4:Unknown status:No publish;;NCT00941967:Phase 2:Unknown status:No publish;;NCT00483405:Phase 2:Completed:Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, Woods L, Moore DT, O'Neil BH. Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma. Gastrointest Cancer Res. 2011 May;4(3):78-83.;;NCT00471484:Phase 2:Unknown status:Ang MK, Poon D, Foo KF, Chung YF, Chow P, Wan WK, Thng CH, Ooi L. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematol Oncol Stem Cell Ther. 2008 Jul-Sep;1(3):159-65.;;NCT00052364:Phase 2:Completed:No publish;;NCT00861783:Phase 1:Completed:Jimeno A, Chan A, Cusatis G, Zhang X, Wheelhouse J, Solomon A, Chan F, Zhao M, Cosenza SC, Ramana Reddy MV, Rudek MA, Kulesza P, Donehower RC, Reddy EP, Hidalgo M. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009 Jan 29;28(4):610-8. doi: 10.1038/onc.2008.424. Epub 2008 Nov 24.;;NCT00507585:Phase 1:Completed:No publish;;NCT00980239:Phase 1:Completed:No publish;;NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT01775501:Phase 2:Active, not recruiting:No publish;;NCT00304135:Phase 2|Phase 3:Completed:Phelip JM, Vendrely V, Rostain F, Subtil F, Jouve JL, Gasmi M, Michel P, Le Malicot K, Smith D, Seitz JF, Fauchart JP, Martin P, Bennouna J, Morin T, Bonnet I, Maingon P, Lepage C, Chauffert B. Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: F��d��ration Francophone de Canc��rologie Digestive 9902 phase II randomised study. Eur J Cancer. 2014 Nov;50(17):2975-82. doi: 10.1016/j.ejca.2014.08.013. Epub 2014 Sep 17.;;NCT01525069:Phase 1:Recruiting:No publish;;NCT01313377:Phase 3:Completed:No publish;;NCT00103298:Phase 2:Completed:No publish;;NCT00987766:Phase 1:Completed:No publish;;NCT00003427:Phase 1:Completed:Kemeny N, Tong W, Gonen M, Stockman J, Di Lauro C, Teitcher J, White P, Price C, Saltz L, Sharma S, Graham MA. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Ann Oncol. 2002 Sep;13(9):1490-6.;;NCT01042691:Phase 1:Completed:No publish;;NCT02529774:Phase 2|Phase 3:Not yet recruiting:No publish;;NCT01643499:Phase 1:Active, not recruiting:No publish;;NCT02557490:Phase 4:Unknown status:No publish;;NCT02380131:Phase 4:Unknown status:No publish;;NCT03493048:Phase 2:Recruiting:No publish;;NCT03493061:Phase 2:Recruiting:No publish;;NCT01511146:Phase 2:Unknown status:No publish;;NCT01384994:Phase 2:Unknown status:No publish;;NCT03500874:Phase 3:Recruiting:No publish;;NCT01959061:Phase 4:Recruiting:No publish;;NCT00557557:Phase 1:Completed:No publish;;NCT00101270:Phase 1:Completed:No publish;;NCT00091182:Phase 2:Completed:No publish;;NCT01442935:Phase 2:Active, not recruiting:No publish;;NCT01348412:Phase 2:Completed:No publish;;NCT00156975:Phase 3:Unknown status:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT00274885:Phase 4:Unknown status:No publish;;NCT00005860:Phase 1:Completed:No publish;;NCT02129322:Phase 2:Not yet recruiting:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT03578874:Phase 2:Recruiting:No publish;;NCT02716766:Phase 2:Recruiting:No publish;;NCT02426450:Phase 2:Unknown status:No publish;;NCT00559455:Phase 2:Completed:No publish;;NCT00471965:Phase 3:Completed:No publish;;NCT00280618:Phase 2:Completed:No publish;;NCT00142467:Phase 2:Completed:No publish;;NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.;;NCT00408551:Phase 2:Unknown status:No publish;;NCT00438737:Phase 2:Unknown status:No publish;;NCT01226719:Phase 2:Completed:No publish;;NCT00803647:Phase 2:Completed:No publish;;NCT00005077:Phase 1:Completed:No publish;;NCT00006479:Phase 3:Unknown status:Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009 Sep;16(9):2385-90. doi: 10.1245/s10434-009-0492-7. Epub 2009 Jun 25. Review.;;NCT01022541:Phase 2:Completed:No publish;;NCT02885753:Phase 3:Recruiting:No publish;;NCT02885753:Phase 3:Recruiting:No publish;;NCT00482222:Phase 3:Unknown status:No publish;;NCT00513266:Phase 2:Unknown status:No publish;;NCT00003834:Phase 2:Completed:Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005 Dec 20;23(36):9243-9. Epub 2005 Oct 17.;;NCT00006062:Phase 1:Completed:No publish;;NCT02494973:Phase 2|Phase 3:Recruiting:No publish;;NCT02494973:Phase 2|Phase 3:Recruiting:No publish;;NCT00006050:Phase 2:Unknown status:Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.;;NCT01802645:Phase 2:Recruiting:No publish;;NCT00544349:Phase 2:Completed:No publish;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.;;NCT00492999:Phase 2:Active, not recruiting:No publish;;NCT00026234:Phase 2:Completed:No publish;;NCT00056030:Phase 2:Completed:No publish	No
medi6469	NCT02559024:Phase 1:Active, not recruiting:No publish	No
p53	NCT02561546:Phase 2:Unknown status:No publish	No
trans-catheter	NCT02561546:Phase 2:Unknown status:No publish	No
ro7070179	NCT02564614:Phase 1:Completed:No publish	No
mln0128	NCT02575339:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT02575339:Phase 1|Phase 2:Active, not recruiting:No publish	No
peginterferon	NCT02576964:Phase 2:Completed:No publish;;NCT03253250:Phase 4:Recruiting:No publish;;NCT00834860:Phase 4:Unknown status:No publish	No
individualized	NCT02580253:Phase 2:Not yet recruiting:No publish	No
mfolfox6	NCT02580253:Phase 2:Not yet recruiting:No publish;;NCT03192644:Phase 3:Recruiting:No publish;;NCT03192618:Phase 3:Recruiting:No publish;;NCT02494973:Phase 2|Phase 3:Recruiting:No publish;;NCT02102789:Phase 3:Recruiting:No publish	No
systemic	NCT02584556:Phase 2|Phase 3:Unknown status:No publish	No
transcatheter	NCT02584556:Phase 2|Phase 3:Unknown status:No publish	No
s-adenosyl	NCT02586285:Phase 1:Unknown status:No publish	No
eadm	NCT02630108:Phase 3:Recruiting:Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.	No
ultra-fluid	NCT02630108:Phase 3:Recruiting:Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. doi: 10.3322/caac.21254. Epub 2015 Jan 5.	No
epirubicin(eadm)	NCT02638857:Phase 1|Phase 2:Unknown status:No publish	No
enzalutamide	NCT02642913:Phase 1|Phase 2:Recruiting:No publish;;NCT02642913:Phase 1|Phase 2:Recruiting:No publish;;NCT02528643:Phase 2:Active, not recruiting:No publish	Enzalutamide (恩杂鲁胺):AR#p.F876L耐药性增加||AR#p.F877L耐药性增加||AR#p.T878A敏感性增加
donafenib	NCT02645981:Phase 2|Phase 3:Recruiting:No publish	No
transarterial	NCT02646137:Phase 3:Recruiting:No publish	No
smoked	NCT02649153:Phase 3:Recruiting:You XM, Mo XS, Ma L, Zhong JH, Qin HG, Lu Z, Xiang BD, Wu FX, Zhao XH, Tang J, Pang YH, Chen J, Li LQ. Randomized Clinical Trial Comparing Efficacy of Simo Decoction and Acupuncture or Chewing Gum Alone on Postoperative Ileus in Patients With Hepatocellular Carcinoma After Hepatectomy. Medicine (Baltimore). 2015 Nov;94(45):e1968. doi: 10.1097/MD.0000000000001968.	No
gum	NCT02649153:Phase 3:Recruiting:You XM, Mo XS, Ma L, Zhong JH, Qin HG, Lu Z, Xiang BD, Wu FX, Zhao XH, Tang J, Pang YH, Chen J, Li LQ. Randomized Clinical Trial Comparing Efficacy of Simo Decoction and Acupuncture or Chewing Gum Alone on Postoperative Ileus in Patients With Hepatocellular Carcinoma After Hepatectomy. Medicine (Baltimore). 2015 Nov;94(45):e1968. doi: 10.1097/MD.0000000000001968.	No
metatinib	NCT02650375:Phase 1:Recruiting:No publish	No
sitagliptin	NCT02650427:Phase 1:Recruiting:No publish	No
her2bi-armed	NCT02662348:Phase 1:Unknown status:No publish	No
rose	NCT02693067:Phase 1:Recruiting:No publish	No
18f-fluoromisonidazole	NCT02695628:Phase 2:Recruiting:No publish	No
tai-gpc3-cart	NCT02715362:Phase 1|Phase 2:Recruiting:No publish	No
mtl-cebpa	NCT02716012:Phase 1:Recruiting:No publish	No
vxm01	NCT02718430:Phase 1:Active, not recruiting:No publish	No
adjuvant	NCT02738697:Phase 3:Recruiting:Qin S, Cheng Y, Liang J, Shen L, Bai Y, Li J, Fan J, Liang L, Zhang Y, Wu G, Rau KM, Yang TS, Jian Z, Liang H, Sun Y. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist. 2014 Nov;19(11):1169-78. doi: 10.1634/theoncologist.2014-0190. Epub 2014 Sep 15.;;NCT01088581:Phase 3:Completed:No publish	No
0.9%	NCT02744248:Phase 1:Completed:No publish;;NCT01782573:Phase 4:Completed:No publish	No
iop	NCT02744248:Phase 1:Completed:No publish;;NCT03407495:Phase 2:Not yet recruiting:No publish	No
whole	NCT02753881:Phase 1:Recruiting:No publish	No
superselective	NCT02753881:Phase 1:Recruiting:No publish	No
medi4736	NCT02754856:Phase 1:Recruiting:No publish;;NCT02572687:Phase 1:Active, not recruiting:No publish	No
tefinostat	NCT02759601:Phase 1|Phase 2:Active, not recruiting:No publish	No
oxaliplatin(oxa),	NCT02767375:Phase 2|Phase 3:Recruiting:Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol. 2015 May-Jun;16(3):465-522. doi: 10.3348/kjr.2015.16.3.465. Epub 2015 May 13.	No
simeprevir	NCT02771405:Phase 3:Recruiting:No publish	No
daclatasvir	NCT02771405:Phase 3:Recruiting:No publish	No
ledipasvir	NCT02771405:Phase 3:Recruiting:No publish	No
sofosbuvir	NCT02771405:Phase 3:Recruiting:No publish;;NCT01559844:Phase 2:Completed:No publish	No
ribavirin	NCT02771405:Phase 3:Recruiting:No publish;;NCT01559844:Phase 2:Completed:No publish	No
inc280	NCT02795429:Phase 1|Phase 2:Recruiting:No publish;;NCT01737827:Phase 2:Recruiting:No publish	No
somatostatin	NCT02799212:Phase 3:Recruiting:No publish;;NCT00386984:Phase 3:Completed:Allgaier HP, Becker G, Blum HE. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide]. Dtsch Med Wochenschr. 2000 Mar 17;125(11):320. German.	No
anlotinib	NCT02809534:Phase 2:Recruiting:No publish	No
entecavir	NCT02829359:Phase 2|Phase 3:Completed:No publish;;NCT02650271:Phase 2|Phase 3:Recruiting:Ke Y, Ma L, You XM, Huang SX, Liang YR, Xiang BD, Li LQ, Zhong JH. Antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med. 2013 Sep;10(3):158-64. doi: 10.7497/j.issn.2095-3941.2013.03.006.	No
h3b-6527	NCT02834780:Phase 1:Recruiting:No publish	No
ad-p53	NCT02842125:Phase 1|Phase 2:Not yet recruiting:No publish	No
xeloda	NCT02842125:Phase 1|Phase 2:Not yet recruiting:No publish	No
keytruda	NCT02842125:Phase 1|Phase 2:Not yet recruiting:No publish	No
cc-122	NCT02859324:Phase 1|Phase 2:Recruiting:No publish	No
5	NCT02885753:Phase 3:Recruiting:No publish	Arn-509:AR#p.F877L耐药性增加||AR#p.T878A敏感性增加
cytoxan	NCT02905188:Phase 1:Not yet recruiting:No publish	No
acetaminophen	NCT02911961:Phase 4:Not yet recruiting:No publish	No
peri-operative	NCT02912052:Phase 3:Not yet recruiting:No publish	No
postoperative	NCT02912052:Phase 3:Not yet recruiting:No publish	No
yang	NCT02927626:Early Phase 1:Recruiting:No publish	No
routine	NCT02927626:Early Phase 1:Recruiting:No publish	No
abc294640	NCT02939807:Phase 2:Recruiting:No publish	No
shr-1210	NCT02942329:Phase 1|Phase 2:Recruiting:No publish	No
nis793	NCT02947165:Phase 1:Recruiting:No publish	No
pdr001	NCT02947165:Phase 1:Recruiting:No publish;;NCT02988440:Phase 1:Recruiting:No publish;;NCT02795429:Phase 1|Phase 2:Recruiting:No publish	No
car-t	NCT02959151:Phase 1|Phase 2:Recruiting:No publish	No
simvastatin	NCT02968810:Phase 2:Recruiting:No publish	No
best	NCT02971696:Phase 3:Completed:No publish;;NCT01655693:Phase 3:Active, not recruiting:No publish;;NCT00508001:Phase 2:Completed:No publish	No
p03277	NCT02973516:Phase 2:Recruiting:No publish	No
5-fu,	NCT02987699:Phase 2:Recruiting:Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9.	No
normal	NCT02987907:Phase 3:Recruiting:No publish	No
trans-arterial	NCT03007225:Phase 4:Completed:No publish	No
genexol-pm	NCT03008512:Phase 2:Recruiting:No publish	No
5fluorouracil	NCT03017326:Phase 3:Recruiting:No publish	No
atorvastatin	NCT03024684:Phase 4:Recruiting:No publish;;NCT03275376:Phase 2:Recruiting:No publish	No
tilmanocept	NCT03029988:Phase 1:Recruiting:No publish	No
folfiri/folfox/capeox	NCT03031444:Phase 2|Phase 3:Recruiting:Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21.	No
lipotecan	NCT03035006:Phase 1|Phase 2:Recruiting:No publish;;NCT02267213:Phase 2:Completed:No publish	No
hydroxychloroquine	NCT03037437:Phase 2:Recruiting:No publish	No
arm	NCT03044587:Phase 2:Recruiting:No publish;;NCT03044587:Phase 2:Recruiting:No publish	No
cbt-501	NCT03053466:Phase 1:Recruiting:No publish	No
int230-6	NCT03058289:Phase 1|Phase 2:Recruiting:No publish	No
sf1126	NCT03059147:Phase 1:Recruiting:No publish	No
parecoxib	NCT03059238:Phase 3:Recruiting:Lv N, Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol. 2016 Oct;26(10):3492-9. doi: 10.1007/s00330-016-4207-8. Epub 2016 Jan 22.	No
controlled-release	NCT03059238:Phase 3:Recruiting:Lv N, Kong Y, Mu L, Pan T, Xie Q, Zhao M. Effect of perioperative parecoxib sodium on postoperative pain control for transcatheter arterial chemoembolization for inoperable hepatocellular carcinoma: a prospective randomized trial. Eur Radiol. 2016 Oct;26(10):3492-9. doi: 10.1007/s00330-016-4207-8. Epub 2016 Jan 22.	No
folfox4	NCT03092895:Phase 2:Recruiting:No publish;;NCT02069041:Phase 1:Completed:No publish;;NCT02534337:Phase 2|Phase 3:Unknown status:No publish;;NCT02527772:Phase 2|Phase 3:Active, not recruiting:Lombardi G, Zustovich F, Farinati F, Cillo U, Vitale A, Zanus G, Donach M, Farina M, Zovato S, Pastorelli D. Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study. Cancer. 2011 Jan 1;117(1):125-33. doi: 10.1002/cncr.25578. Epub 2010 Aug 31.|Qin S, Bai Y, Lim HY, Thongprasert S, Chao Y, Fan J, Yang TS, Bhudhisawasdi V, Kang WK, Zhou Y, Lee JH, Sun Y. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol. 2013 Oct 1;31(28):3501-8. doi: 10.1200/JCO.2012.44.5643. Epub 2013 Aug 26.;;NCT02452853:Phase 2:Unknown status:No publish;;NCT00874406:Phase 4:Unknown status:No publish	No
apatinib	NCT03092895:Phase 2:Recruiting:No publish;;NCT02702323:Phase 2|Phase 3:Not yet recruiting:No publish;;NCT02727309:Phase 1|Phase 2:Recruiting:No publish;;NCT02942329:Phase 1|Phase 2:Recruiting:No publish;;NCT02772029:Phase 1|Phase 2:Unknown status:No publish;;NCT03511703:Phase 2:Not yet recruiting:No publish;;NCT03261791:Phase 2:Recruiting:No publish;;NCT03114085:Phase 2:Not yet recruiting:No publish;;NCT03046979:Phase 2:Recruiting:No publish;;NCT02329860:Phase 3:Active, not recruiting:No publish;;NCT01192971:Phase 2:Completed:No publish	Lapatinib (拉帕替尼):ERBB2#p.D769H敏感性增加||ERBB2#p.D769Y敏感性增加||ERBB4#p.E317K敏感性增加||ERBB4#p.E452K敏感性增加||EGFR#p.E690K敏感性增加||ERBB4#p.E872K敏感性增加||ERBB3#p.G284R敏感性增加||ERBB2#p.G309A敏感性增加||ERBB4#p.H809G耐药性增加||ERBB2#p.K753E耐药性增加||ERBB3#p.P262H敏感性增加||ERBB3#p.Q809R敏感性增加||ERBB4#p.R393W敏感性增加||ERBB4#p.R544W敏感性增加||ERBB2#p.R896C敏感性增加||ERBB2#p.V659E敏感性增加||ERBB2#p.V777L敏感性增加||ERBB2#p.V842I敏感性增加
xl888	NCT03095781:Phase 1:Recruiting:No publish	No
kn035	NCT03101488:Phase 1:Recruiting:No publish	No
bumetanide	NCT03107416:Phase 1|Phase 2:Recruiting:No publish	No
milciclib	NCT03109886:Phase 2:Recruiting:No publish	No
68gallium	NCT03116945:Phase 2:Recruiting:Gharib AM, Thomasson D, Li KC. Molecular imaging of hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S153-8.	No
gpc3-cart	NCT03130712:Phase 1|Phase 2:Recruiting:No publish	No
drug	NCT03143270:Early Phase 1:Recruiting:No publish	No
nivolumab	NCT03143270:Early Phase 1:Recruiting:No publish;;NCT03572582:Phase 2:Recruiting:No publish;;NCT03203304:Phase 1:Recruiting:No publish;;NCT03299946:Phase 1:Recruiting:No publish;;NCT02423343:Phase 1|Phase 2:Recruiting:No publish;;NCT03071094:Phase 1|Phase 2:Recruiting:No publish;;NCT02859324:Phase 1|Phase 2:Recruiting:No publish;;NCT03511222:Phase 1:Not yet recruiting:No publish;;NCT03222076:Phase 2:Recruiting:No publish;;NCT03418922:Phase 1:Recruiting:No publish;;NCT03382886:Phase 1:Recruiting:No publish;;NCT02576509:Phase 3:Active, not recruiting:No publish	No
incb062079	NCT03144661:Phase 1:Recruiting:No publish	No
pregabalin	NCT03151213:Phase 4:Recruiting:No publish	No
folfox	NCT03164382:Phase 3:Recruiting:No publish;;NCT00103298:Phase 2:Completed:No publish;;NCT00866944:Phase 2:Completed:No publish;;NCT02774187:Phase 3:Active, not recruiting:Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS One. 2015 Mar 5;10(3):e0119312. doi: 10.1371/journal.pone.0119312. eCollection 2015.;;NCT03469479:Phase 3:Recruiting:No publish;;NCT03048123:Phase 2:Completed:No publish;;NCT02981498:Phase 2:Recruiting:He MK, Zou RH, Li QJ, Zhou ZG, Shen JX, Zhang YF, Yu ZS, Xu L, Shi M. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. Cardiovasc Intervent Radiol. 2018 May;41(5):734-743. doi: 10.1007/s00270-017-1874-z. Epub 2018 Jan 11.;;NCT02973685:Phase 3:Recruiting:No publish;;NCT00006479:Phase 3:Unknown status:Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. Ann Surg Oncol. 2009 Sep;16(9):2385-90. doi: 10.1245/s10434-009-0492-7. Epub 2009 Jun 25. Review.;;NCT00006050:Phase 2:Unknown status:Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M; gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 2005 Aug 1;23(22):4881-7. Epub 2005 Jul 11.;;NCT00008294:Phase 1:Completed:Kemeny N, Capanu M, D'Angelica M, Jarnagin W, Haviland D, Dematteo R, Fong Y. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009 Jul;20(7):1236-41. doi: 10.1093/annonc/mdn769. Epub 2009 Feb 20.	No
il-2	NCT03175705:Phase 1:Recruiting:No publish;;NCT03175679:Phase 1:Recruiting:No publish	No
tegafur	NCT03175705:Phase 1:Recruiting:No publish;;NCT03175679:Phase 1:Recruiting:No publish	No
metformin	NCT03184493:Phase 3:Recruiting:No publish;;NCT02145559:Phase 1:Active, not recruiting:No publish;;NCT02431676:Phase 2:Active, not recruiting:No publish;;NCT02672488:Phase 2:Recruiting:No publish	No
celebrex	NCT03184493:Phase 3:Recruiting:No publish;;NCT03184493:Phase 3:Recruiting:No publish	No
bushen-jianpi	NCT03189992:Phase 1:Recruiting:No publish	No
cinobufotalin	NCT03189992:Phase 1:Recruiting:No publish	No
epidoxorubicin	NCT03192644:Phase 3:Recruiting:No publish	No
c188-9	NCT03195699:Phase 1:Recruiting:No publish	No
perflutren	NCT03199274:Early Phase 1:Recruiting:No publish	No
np-g2-044	NCT03199586:Phase 1:Recruiting:No publish	No
ima970a	NCT03203005:Phase 1|Phase 2:Recruiting:No publish	No
urea	NCT03212625:Phase 4:Recruiting:No publish	No
placebos	NCT03212625:Phase 4:Recruiting:No publish	No
primovist	NCT03215355:Phase 4:Not yet recruiting:No publish	No
arq	NCT03230318:Phase 2:Recruiting:No publish;;NCT01752920:Phase 1|Phase 2:Active, not recruiting:No publish;;NCT01656265:Phase 1:Completed:No publish;;NCT00988741:Phase 2:Completed:No publish;;NCT00802555:Phase 1:Completed:No publish	No
cpg	NCT03235167:Phase 1:Not yet recruiting:No publish	No
huachansu	NCT03236636:Phase 3:Not yet recruiting:No publish;;NCT01715532:Phase 2:Unknown status:No publish	No
icaritin	NCT03236649:Phase 3:Not yet recruiting:No publish;;NCT03236636:Phase 3:Not yet recruiting:No publish;;NCT01972672:Phase 2:Unknown status:No publish	No
chiauranib	NCT03245190:Phase 1:Recruiting:No publish	No
etv；tdf；adv	NCT03253250:Phase 4:Recruiting:No publish	No
meclizine	NCT03253289:Phase 1:Recruiting:No publish	No
guadecitabine	NCT03257761:Phase 1:Recruiting:No publish	No
opdivo	NCT03259867:Phase 2:Recruiting:No publish;;NCT02842125:Phase 1|Phase 2:Not yet recruiting:No publish	No
arginine	NCT03278444:Phase 3:Recruiting:No publish	No
trimetazidine	NCT03278444:Phase 3:Recruiting:No publish	No
defined	NCT03278925:Phase 1:Not yet recruiting:No publish	No
avelumab	NCT03289533:Phase 1:Recruiting:No publish;;NCT03389126:Phase 2:Recruiting:No publish	No
btg-002814	NCT03291379:Early Phase 1:Recruiting:No publish	No
fmiso	NCT03303469:Phase 2:Recruiting:No publish	No
gns561	NCT03316222:Phase 1|Phase 2:Recruiting:No publish	No
fate-nk100	NCT03319459:Phase 1:Recruiting:No publish	No
trastuzumab	NCT03319459:Phase 1:Recruiting:No publish;;NCT01953926:Phase 2:Recruiting:No publish	Trastuzumab (曲妥珠单抗):ERBB2#p.C311R敏感性增加||ERBB2#p.C311R敏感性增加||ERBB2#p.C334S敏感性增加||ERBB2#p.D769H敏感性增加||ERBB2#p.D769Y敏感性增加||ERBB2#p.E321G敏感性增加||ERBB3#p.G284R敏感性增加||ERBB2#p.G309E敏感性增加||ERBB2#p.G309E敏感性增加||ERBB2#p.G776L敏感性增加||ERBB3#p.P262H敏感性增加||ERBB3#p.Q809R敏感性增加||AKT3#p.R247C耐药性增加||ERBB2#p.R896C敏感性增加||ERBB2#p.S310F敏感性增加||ERBB2#p.S310F敏感性增加||ERBB2#p.S310Y敏感性增加||ERBB2#p.S310Y敏感性增加
acetylsalicylic	NCT03326791:Phase 2:Recruiting:No publish	No
cdx-1140	NCT03329950:Phase 1:Recruiting:No publish	No
cobimetinib	NCT03340558:Phase 2:Not yet recruiting:No publish	Vemurafenib + Cobimetinib:BRAF#p.V600E敏感性增加||BRAF#p.V600K敏感性增加
regorafenib(stivarga,	NCT03347292:Phase 1:Recruiting:No publish	No
terlipressinum	NCT03352349:Phase 2:Recruiting:No publish	No
pembrolizumab	NCT03397654:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT02509507:Phase 1:Recruiting:No publish;;NCT02940496:Phase 1|Phase 2:Recruiting:No publish;;NCT03347292:Phase 1:Recruiting:No publish;;NCT03511222:Phase 1:Not yet recruiting:No publish;;NCT01174121:Phase 2:Recruiting:No publish;;NCT03519997:Phase 2:Recruiting:No publish;;NCT03337841:Phase 2:Not yet recruiting:No publish;;NCT03163992:Phase 2:Recruiting:No publish;;NCT03006926:Phase 1:Recruiting:No publish;;NCT03419481:Phase 2:Recruiting:No publish;;NCT02658019:Phase 2:Active, not recruiting:No publish	No
standard	NCT03398291:Phase 3:Not yet recruiting:No publish	No
rintatolimod	NCT03403634:Early Phase 1:Recruiting:No publish	No
lumason	NCT03407001:Early Phase 1:Recruiting:No publish	No
bgb-a317	NCT03419897:Phase 2:Recruiting:No publish;;NCT03412773:Phase 3:Recruiting:No publish	No
icosapent	NCT03428477:Phase 3:Recruiting:No publish	No
lenvatinib	NCT03433703:Phase 2:Recruiting:No publish;;NCT03418922:Phase 1:Recruiting:No publish;;NCT03006926:Phase 1:Recruiting:No publish;;NCT02953743:Phase 1:Active, not recruiting:No publish;;NCT01761266:Phase 3:Active, not recruiting:No publish	Lenvatinib (乐伐替尼):SDHB#p.V140F敏感性增加
atezolizumab	NCT03434379:Phase 3:Recruiting:No publish	No
pt-112	NCT03439761:Phase 1|Phase 2:Recruiting:No publish	No
para-toluenesulfonamide	NCT03447951:Phase 2:Not yet recruiting:No publish	No
shr	NCT03463876:Phase 2:Recruiting:No publish	No
haic	NCT03468231:Phase 3:Recruiting:No publish;;NCT03468231:Phase 3:Recruiting:No publish;;NCT02856126:Phase 3:Recruiting:No publish	No
5-fluorouracil	NCT03493048:Phase 2:Recruiting:No publish;;NCT03366155:Phase 2:Not yet recruiting:No publish;;NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT00941655:Phase 3:Completed:Rudloff U, Langan RC, Mullinax JE, Beane JD, Steinberg SM, Beresnev T, Webb CC, Walker M, Toomey MA, Schrump D, Pandalai P, Stojadinovic A, Avital I. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol. 2014 Sep;110(3):275-84. doi: 10.1002/jso.23633. Epub 2014 Jul 5.;;NCT01226719:Phase 2:Completed:No publish	No
aslan001	NCT03499626:Phase 1|Phase 2:Recruiting:No publish	No
fudr	NCT03500874:Phase 3:Recruiting:No publish	No
5fu	NCT03500874:Phase 3:Recruiting:No publish	No
cgx1321	NCT03507998:Phase 1:Recruiting:No publish	No
nivolumab,	NCT03510871:Phase 2:Not yet recruiting:No publish	No
vorolanib	NCT03511222:Phase 1:Not yet recruiting:No publish	No
babaodan	NCT03515369:Phase 4:Not yet recruiting:No publish	No
ts-1	NCT03519074:Phase 2:Recruiting:No publish	No
etoposide	NCT03533582:Phase 2|Phase 3:Recruiting:No publish;;NCT00007813:Phase 1:Unknown status:Leung W, Chen AR, Klann RC, Moss TJ, Davis JM, Noga SJ, Cohen KJ, Friedman AD, Small D, Schwartz CL, Borowitz MJ, Wharam MD, Paidas CN, Long CA, Karandish S, McMannis JD, Kastan MB, Civin CI. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 1998 Nov;22(10):971-9.;;NCT00002854:Phase 1:Completed:No publish;;NCT03017326:Phase 3:Recruiting:No publish;;NCT00003597:Phase 1:Completed:Angiolillo AL, Davenport V, Bonilla MA, van de Ven C, Ayello J, Militano O, Miller LL, Krailo M, Reaman G, Cairo MS; Children's Oncology Group. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Clin Cancer Res. 2005 Apr 1;11(7):2644-50.	No
durvalumab	NCT03539822:Phase 1:Not yet recruiting:No publish;;NCT03298451:Phase 3:Recruiting:No publish;;NCT03298451:Phase 3:Recruiting:No publish;;NCT03298451:Phase 3:Recruiting:No publish	No
administration	NCT03551444:Phase 3:Recruiting:No publish	No
nab-paclitaxel	NCT03563170:Phase 1|Phase 2:Not yet recruiting:No publish;;NCT02423239:Phase 1:Unknown status:No publish	No
tace	NCT03572582:Phase 2:Recruiting:No publish;;NCT01217034:Phase 2:Active, not recruiting:No publish;;NCT02018757:Phase 2:Unknown status:No publish;;NCT02018757:Phase 2:Unknown status:No publish;;NCT03048123:Phase 2:Completed:No publish;;NCT02973685:Phase 3:Recruiting:No publish;;NCT02956772:Phase 2:Not yet recruiting:No publish;;NCT02856126:Phase 3:Recruiting:No publish;;NCT02436902:Phase 3:Recruiting:No publish;;NCT02418988:Phase 2:Unknown status:No publish;;NCT02418988:Phase 2:Unknown status:No publish;;NCT03007225:Phase 4:Completed:No publish;;NCT00921531:Phase 3:Unknown status:No publish	No
cvm-1118	NCT03582618:Phase 2:Not yet recruiting:No publish	No
lutetium	NCT03590119:Phase 2|Phase 3:Not yet recruiting:No publish	No
atg-008	NCT03591965:Phase 2:Not yet recruiting:No publish	No
obi-3424	NCT03592264:Phase 1|Phase 2:Recruiting:No publish	No
